<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83533</article-id><article-id pub-id-type="doi">10.7554/eLife.83533</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-293498"><name><surname>Feng</surname><given-names>Xing</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2253-4180</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293509"><name><surname>Sun</surname><given-names>Ruifeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293500"><name><surname>Lee</surname><given-names>Moonyoung</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293501"><name><surname>Chen</surname><given-names>Xinyue</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8288-7685</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-125455"><name><surname>Guo</surname><given-names>Shangqin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1157-0423</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293502"><name><surname>Geng</surname><given-names>Huimin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240022"><name><surname>Müschen</surname><given-names>Marcus</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-63935"><name><surname>Choi</surname><given-names>Jungmin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8614-0973</contrib-id><email>jungminchoi@korea.ac.kr</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-126645"><name><surname>Pereira</surname><given-names>Joao Pedro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5694-4938</contrib-id><email>joao.pereira@yale.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Immunobiology and Yale Stem Cell Center, Yale University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Center of Molecular and Cellular Oncology and Department of Immunobiology, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/047dqcg40</institution-id><institution>Department of Biomedical Sciences, Korea University College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Cell Biology and Yale Stem Cell Center, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Laboratory Medicine, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Genetics, School of Medicine, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Méndez-Ferrer</surname><given-names>Simón</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83533</elocation-id><history><date date-type="received" iso-8601-date="2022-09-17"><day>17</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-10"><day>10</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-09-28"><day>28</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.23.509256"/></event></pub-history><permissions><copyright-statement>© 2023, Feng et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Feng et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83533-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83533-figures-v2.pdf"/><abstract><p>Acute lymphoblastic and myeloblastic leukemias (ALL and AML) have been known to modify the bone marrow microenvironment and disrupt non-malignant hematopoiesis. However, the molecular mechanisms driving these alterations remain poorly defined. Using mouse models of ALL and AML, here we show that leukemic cells turn off lymphopoiesis and erythropoiesis shortly after colonizing the bone marrow. ALL and AML cells express lymphotoxin α1β2 and activate lymphotoxin beta receptor (LTβR) signaling in mesenchymal stem cells (MSCs), which turns off IL7 production and prevents non-malignant lymphopoiesis. We show that the DNA damage response pathway and CXCR4 signaling promote lymphotoxin α1β2 expression in leukemic cells. Genetic or pharmacological disruption of LTβR signaling in MSCs restores lymphopoiesis but not erythropoiesis, reduces leukemic cell growth, and significantly extends the survival of transplant recipients. Similarly, CXCR4 blocking also prevents leukemia-induced IL7 downregulation and inhibits leukemia growth. These studies demonstrate that acute leukemias exploit physiological mechanisms governing hematopoietic output as a strategy for gaining competitive advantage.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>lymphotoxin beta receptor</kwd><kwd>interleukin-7</kwd><kwd>leukemia</kwd><kwd>CXCR4</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI113040</award-id><principal-award-recipient><name><surname>Pereira</surname><given-names>Joao Pedro</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21AI133060</award-id><principal-award-recipient><name><surname>Pereira</surname><given-names>Joao Pedro</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35CA197628</award-id><principal-award-recipient><name><surname>Müschen</surname><given-names>Marcus</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI164692</award-id><principal-award-recipient><name><surname>Müschen</surname><given-names>Marcus</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21AI146648</award-id><principal-award-recipient><name><surname>Müschen</surname><given-names>Marcus</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32 DK007356</award-id><principal-award-recipient><name><surname>Feng</surname><given-names>Xing</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Acute lymphoblastic and myeloblastic leukemias activate lymphotoxin beta receptor in mesenchymal stem cells in the bone marrow to turn off interleukin-7 production and lymphopoiesis and gain competitive advantage.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Blood cell production is a tightly regulated process important for organismal homeostasis. All blood cells develop from a dedicated hematopoietic stem cell (HSC) that colonizes specialized niches in the bone marrow (BM) formed predominantly by mesenchymal stem cells (MSCs) and endothelial cells (ECs) (<xref ref-type="bibr" rid="bib40">Morrison and Scadden, 2014</xref>; <xref ref-type="bibr" rid="bib44">Pinho and Frenette, 2019</xref>; <xref ref-type="bibr" rid="bib49">Sugiyama et al., 2019</xref>). Within these niches, HSCs and hematopoietic progenitors receive critical signals for long-term HSC maintenance and for differentiation into lymphoid, myeloid, and erythroid lineages (<xref ref-type="bibr" rid="bib49">Sugiyama et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Miao et al., 2020</xref>). However, most hematopoietic cytokines act in a short-range manner, and thus hematopoietic stem and progenitor cells rely on localization cues such as CXCL12 for accessing growth factors produced by MSCs and ECs (<xref ref-type="bibr" rid="bib42">Noda et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Tzeng et al., 2011</xref>; <xref ref-type="bibr" rid="bib21">Ding and Morrison, 2013</xref>; <xref ref-type="bibr" rid="bib24">Greenbaum et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Cordeiro Gomes et al., 2016</xref>).</p><p>While HSCs and uncommitted hematopoietic progenitors are critically dependent on stem cell factor (SCF, encoded by <italic>Kitl</italic>), committed progenitors require lineage-specific signals, such as IL7 for lymphocytes, IL15 for NK cells, or M-CSF for monocytes and macrophages. Importantly, most hematopoietic cytokines are produced by MSCs and by a subset of ECs in the BM (<xref ref-type="bibr" rid="bib38">Miao et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Noda et al., 2011</xref>; <xref ref-type="bibr" rid="bib17">Cordeiro Gomes et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Ding et al., 2012</xref>; <xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>; <xref ref-type="bibr" rid="bib16">Comazzetto et al., 2019</xref>; <xref ref-type="bibr" rid="bib50">Tikhonova et al., 2019</xref>). The production of hematopoietic cytokines and chemokines by MSCs and ECs is relatively stable during homeostasis but can change significantly under certain perturbations. For example, systemic inflammation caused by infections enforces the downregulation of multiple hematopoietic cytokines and CXCL12 in the BM (<xref ref-type="bibr" rid="bib53">Ueda et al., 2004</xref>; <xref ref-type="bibr" rid="bib54">Ueda et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Manz and Boettcher, 2014</xref>). Likewise, acute lymphoblastic and myeloblastic leukemias (ALL and AML) also promote the downregulation of multiple cytokines and CXCL12 produced by MSCs and ECs (<xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Hanoun et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Fistonich et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Zehentmeier and Pereira, 2019</xref>). During systemic infection, the coordinated downregulation of certain cytokines (e.g. IL7) and CXCL12 causes a temporary pause in lymphopoiesis that is necessary for an emergent production of short-lived neutrophils and monocytes (<xref ref-type="bibr" rid="bib35">Manz and Boettcher, 2014</xref>). In leukemic states, however, the mechanism(s) promoting cytokine and chemokine downregulation are not well defined, and neither is known if these changes are protective or harmful for the host.</p><p>In humans and in mouse models of B-ALL, leukemic cells use CXCR4 to home to the BM (<xref ref-type="bibr" rid="bib29">Juarez et al., 2007</xref>; <xref ref-type="bibr" rid="bib15">Colmone et al., 2008</xref>; <xref ref-type="bibr" rid="bib55">van den Berk et al., 2014</xref>). However, B-ALL cells do not distribute randomly and seem to reside and proliferate in certain perivascular niches (<xref ref-type="bibr" rid="bib15">Colmone et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Sipkins et al., 2005</xref>). Importantly, CXCL12 production is measurably reduced exclusively in BM niches colonized by B-ALL cells (<xref ref-type="bibr" rid="bib15">Colmone et al., 2008</xref>; <xref ref-type="bibr" rid="bib55">van den Berk et al., 2014</xref>). Furthermore, intact CXCR4 signaling presumably in B-ALL cells is required for downregulation of CXCL12 expression in BM niche cells (<xref ref-type="bibr" rid="bib55">van den Berk et al., 2014</xref>). The fact that CXCR4 expression levels in B-ALL cells inversely correlate with patient outcome suggests that B-ALL-induced changes in the BM microenvironment may favor leukemia progression (<xref ref-type="bibr" rid="bib55">van den Berk et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Cancilla et al., 2020</xref>).</p><p>The BM microenvironment has also been reported to be severely affected in AML patients and in mouse models of AML. Of note, hematopoietic cytokines and chemokines are significantly downregulated along with the re-programing of MSC and EC transcriptomes (<xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Hanoun et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Chandran et al., 2015</xref>; <xref ref-type="bibr" rid="bib23">Geyh et al., 2016</xref>). Although no specific mechanisms have been identified for explaining how AML cells dysregulate MSCs and ECs, some evidence suggests that this may be mediated by direct AML-niche cell interactions (<xref ref-type="bibr" rid="bib28">Hérault et al., 2017</xref>). Thus, a model emerges where leukemia cells attracted to CXCL12-producing BM niches physically interact and re-program MSCs and ECs to reduce CXCL12 levels, possibly reduce hematopoietic output, and in this way favor leukemic cell expansion. However, the molecular mechanisms utilized by leukemia for MSC and EC re-programing and for reducing non-malignant hematopoiesis remain poorly defined.</p><p>In this study, we show that ALL and AML cells preferentially turn off lymphopoiesis and erythropoiesis shortly after seeding the BM. We demonstrate that both B-ALL and AML cells express LTα1β2, the membrane-bound ligand of lymphotoxin beta receptor (LTβR), which enforces IL7 downregulation in LTβR-expressing MSCs. Genetic or pharmacological blockade of LTβR signaling in MSCs restores lymphopoiesis but not erythropoiesis at the onset of leukemia, which in turn reduces leukemic cell growth and extends survival of transplant recipients. These studies demonstrate that leukemic cells exploit molecular mechanisms that confer flexibility in blood cell production to suppress normal hematopoiesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>ALL inhibits non-leukemic hematopoiesis</title><p>Although leukemia alters BM niches, whether these changes directly affect hematopoietic cell production has not been carefully studied. To determine if and which hematopoietic cell lineages are affected by leukemia, we transplanted 3 million pre-B-cell precursor ALL cells expressing the BCR-ABL1 oncogene (from here on referred as ALL; BCR-ABL1 reported by YFP expression) into non-irradiated C57Bl6/J mice and analyzed its impact on lymphoid, myeloid, and erythroid cell production over time. As expected, ALL cells expanded rapidly in BM (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Conversely, non-leukemic developing B cells and mature recirculating B cells declined sharply 2 weeks after ALL transplantation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Monocyte numbers reduced between the first and second weeks by four- to fivefold, but cell numbers recovered to normal levels at 3 weeks (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This contrasted with a moderate twofold decline in neutrophil numbers at 2 weeks that remained stable until 3 weeks (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Changes in immature erythrocytes (Ter119+CD71+ cells) were similar to the reductions seen in B cell progenitors: erythroid cells progressively reduced at 6, 14, and 21 days after ALL transplantation, reaching &gt;10-fold reductions at 3 weeks (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In summary, ALL expansion induces a strong decline in lymphopoiesis and erythropoiesis while their impact on myeloid cell production is modest.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Kinetics of B-ALL growth and impact on hematopoiesis.</title><p>(<bold>A</bold>) B-ALL number. (<bold>B</bold>) Number of non-malignant developing B cell subsets. (<bold>C</bold>) Inflammatory monocytes. (<bold>D</bold>) Neutrophils. (<bold>E</bold>) Immature (Ter119+CD71+) and mature (Ter119+CD71-) red blood cells. Data in all panels show bone marrow cell numbers obtained from wild-type (WT) mice transplanted with 3×10<sup>6</sup> BCR-ABL-expressing B-ALL cells. In all panels, X-axis indicates time (days) after B-ALL transplantation. Bars indicate mean, circles depict individual mice. Data are representative of two independent experiments. **p&lt;0.005; ***p&lt;0.0005 unpaired, two-sided, Student’s <italic>t</italic> test. ###p&lt;0.0005 Mann–Whitney test. ALL, acute lymphoblastic leukemia.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title>ALL induces LTβR signaling in MSCs, downregulates <italic>Il7</italic> expression, and modulates lymphopoiesis</title><p>In previous studies we noted that transplanted ALL cells and Artemis-deficient (pre-leukemic) pre-B cells led to IL7 and CXCL12 downregulation in MSCs (<xref ref-type="bibr" rid="bib22">Fistonich et al., 2018</xref>), which could explain the negative impact of ALL in non-malignant lymphopoiesis. While the mechanism(s) responsible for IL7 and CXCL12 downregulation remained undefined, earlier studies suggested a role for LTβR signaling in BM stromal cells in development of some lymphoid lineages (<xref ref-type="bibr" rid="bib57">Wu et al., 2001</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 2014</xref>). In recent studies, we found that MSCs express LTβR and that LTβR signaling controls IL7 expression in vivo (<xref ref-type="bibr" rid="bib60">Zehentmeier et al., 2022</xref>). Furthermore, when mRNA levels of <italic>LTB</italic> were analyzed in pediatric samples of B-ALL (Children’s Oncology Group Study 9906 for High-Risk Pediatric ALL) and associated with clinical outcome at the time of diagnosis, we noted an inverse correlation between <italic>LTB</italic> transcript abundance and relapse-free survival that reached statistical significance (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). These observations led us to hypothesize that leukemic cells express LTβR ligands and induce LTβR signaling in MSCs in vivo. In mice, BCR-ABL1 expressing pre-B ALL cells also express higher LTα/LTβ amounts than non-leukemic pre-B, immature, and mature B cells (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). The presence of ALL cells in the BM environment did not change LTα and LTβ expression on non-leukemic host pre-B cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Importantly, when mouse ALL cells were engineered to over-express LTα/LTβ, these ALLs induced stronger IL7 downregulation in BM MSCs and were lethal more quickly than empty vector transduced ALL cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–E</xref>). Combined, these studies suggest a pathogenic role for the LTβR pathway in leukemia progression.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Lymphotoxin α1β2 expression in B-ALL cells and therapeutic effect of lymphotoxin beta receptor (LTβR) blocking.</title><p>(<bold>A</bold>) Histograms of LTα and LTβ expression in B-ALL cells and in pre-B cells. Purple, B-ALL; green, non-malignant pre-B cells (CD19+CD93+IgM-cKit-) in bone marrow (BM) of wild-type (WT) mice transplanted with B-ALL cells; blue, non-malignant pre-B cells in BM of WT mice (no B-ALL); filled gray, non-malignant <italic>Ltb</italic>-deficient pre-B cells in BM of <italic>Ltb</italic><sup>-/-</sup> mice. (<bold>B</bold>) LTα and LTβ mean fluorescence intensity (MFI) in developing B cells and ALLs isolated from BM of ALL transplanted mice. (<bold>C</bold>) Experimental design of data described in panels D–H. (<bold>D</bold>) Number of non-malignant developing B cell subsets in BM. (<bold>E</bold>) Immature and mature erythrocyte number. (<bold>F</bold>) Neutrophils. (<bold>G</bold>) Monocytes. (<bold>H</bold>) B-ALL number. Data in panels D–H show BM numbers from WT mice transplanted with 3×10<sup>6</sup> BCR-ABL-expressing B-ALL cells and treated with HEL-Ig or LTβR-Ig (150 µg/mouse) on day 0 and day 5; mice were analyzed on day 8 post ALL transplantation. (<bold>I</bold>) Frequency of mouse survival after B-ALL transplantation following pre-treatment with either HEL-Ig or LTβR-Ig (n=5 per group). Mice were treated with HEL-Ig or LTβR-Ig (150 µg/mouse) every 5 days until endpoint. Bars indicate mean, circles depict individual mice. Data are representative of two independent experiments. *p&lt;0.05; **p&lt;0.005; ***p&lt;0.0005 unpaired, two-sided, Student’s <italic>t</italic> test. ###p&lt;0.0005 Mann–Whitney test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Relationship between lymphotoxin α1β2 abundance and acute lymphoblastic leukemia (ALL) lethality.</title><p>(<bold>A</bold>) mRNA levels of <italic>LTB</italic> were analyzed in microarray datasets (COG P9906) and associated with clinical outcome. Patients in each group were segregated into higher- versus lower-than-median <italic>LTB</italic> mRNA levels. Kaplan–Meier plot shows relapse-free survival probability. Mantel–Cox log-rank tests (two-sided) were used to determine statistical significance. Y-axes indicate time (years). (<bold>B</bold>) Experimental design: impact of LTαβ over-expression in ALL lethality. (<bold>C</bold>) Histogram of LTα expression in empty vector (EV, blue) and LTαβ transduced (pink) ALL cells. (<bold>D</bold>) <italic>Il7</italic>-GFP expression in mesenchymal stem cells (MSCs) of mice engrafted with non-transduced (CTR, gray), empty vector (EV, blue), and LTαβ transduced (pink) ALL cells. (<bold>E</bold>) Survival frequency of mice engrafted with empty vector (EV, blue) or LTαβ transduced (pink) ALL cells (n=5 per group).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To test if LTβR signaling impacts ALL growth and non-malignant hematopoiesis, we transplanted 3 million ALL cells into WT syngeneic recipient mice (C57BL6/J) treated weekly with a soluble LTβR-Ig decoy (a fusion between LTβR ectodomain and the Fc domain of a mouse IgG1 recognizing Hen Egg Lysozyme) or with control Hel-Ig. Transplanted ALL cells reduced lymphopoiesis significantly, which was reverted with LTβR-Ig treatment (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). In contrast, LTβR signaling blockade did not restore erythropoiesis or myelopoiesis (<xref ref-type="fig" rid="fig2">Figure 2E–G</xref>). Importantly, ALL growth was significantly reduced at 2 weeks (<xref ref-type="fig" rid="fig2">Figure 2H</xref>), which reflected in a small but significant extension of mouse survival (<xref ref-type="fig" rid="fig2">Figure 2I</xref>).</p><p>To gain further insight into the mechanisms used by ALL cells for reducing non-malignant hematopoiesis, we analyzed the MSC transcriptome in homeostasis, during ALL expansion, and in mice with ALL but treated with LTβR-Ig. To identify gene expression differences between the three groups, we performed principal component analyses (PCA) on the transcriptome datasets from three to four independent replicates. The first two principal components (PC1 and PC2) represent the main axes of variation within these datasets and explained 46% and 17% of variation, respectively. Samples from control and ALL groups separated by PC1, and within ALL cohorts, samples from LTβR-Ig versus Hel-Ig treated ALL also segregated from each other, thus indicating major transcriptional changes induced by ALL growth in vivo, of which a significant fraction was sensitive to LTβR blocking (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Unsupervised clustering of the top 1000 most variable genes also independently segregated the three groups (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Comparisons between control and ALL treated with Hel-Ig samples revealed 322 differentially expressed genes (DEGs; Padj &lt;0.05, |log2FC|&gt;1), of which 74 were downregulated and 248 were upregulated in MSCs of control mice (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Comparisons between the ALL groups (Hel-Ig versus LTβR-Ig) revealed 226 DEGs of which 149 were upregulated and 77 were downregulated in MSCs of mice with ALL and treated with Hel-Ig (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Gene set enrichment analyses revealed a strong inflammatory gene signature induced by ALL with a strong statistical significance in interferon α- and γ-induced genes, complement, and cytokines IL2, IL6, and TNFα signaling (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Of note, LTβR blocking further increased the interferon stimulated gene signature, while it reduced the expression of genes associated with TNFα signaling (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), consistent with the fact that LTβR is a TNF superfamily member that activates canonical and non-canonical nuclear factor kappa-binding transcription factors (NFκB) (<xref ref-type="bibr" rid="bib43">Norris and Ware, 2007</xref>). Importantly, of the several hematopoietic cytokines expressed by MSCs, KITL, IL7, IGF1, and CSF1 were significantly downregulated by ALL cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These transcriptional changes in MSCs were similar to those described in mice with acute myeloid leukemia (<xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>). However, of these hematopoietic cytokines, only IL7 downregulation was blocked by LTβR-Ig treatment (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Furthermore, blocking other NFκB-inducing cytokines, such as TNFα and IL1β, did not prevent IL7 downregulation nor did it rescue non-malignant lymphopoiesis or myelopoiesis (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–C</xref>) and did not impact ALL expansion in vivo (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Even though ALL cells promoted an interferon-induced gene expression signature in MSCs (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), blocking IFNα or IFNγ signaling did not rescue IL7 downregulation and non-malignant hematopoiesis, nor did it reduce ALL growth in vivo (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E–I</xref>). Combined, these results show a major impact of ALL expansion in the MSC transcriptome, with a large fraction of DEGs being sensitive to LTβR blocking.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Lymphotoxin beta receptor (LTβR)-dependent and -independent transcriptomic changes in mesenchymal stem cells (MSCs) induced by B-ALL.</title><p>(<bold>A</bold>) Principal component analysis (PCA) distribution plot. (<bold>B</bold>) Unsupervised hierarchical clustering and heatmap representation of top 1000 differentially expressed genes. (<bold>C</bold>) GSEA-KEGG pathway alterations in MSCs. (<bold>D</bold>) Hematopoietic cytokines and chemokine mRNA expression. Data in all panels were generated from analyses of MSC bulk RNA sequencing. *p&lt;0.05; **p&lt;0.005; unpaired, two-sided, Student’s <italic>t</italic> test. ALL, acute lymphoblastic leukemia.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Effect of inflammatory cytokines in acute lymphoblastic leukemia (ALL) growth.</title><p>(<bold>A–D</bold>) Comparison between control (Hel-Ig), lymphotoxin beta receptor (LTβR), TNFα, and IL1β blocking in ALL and non-malignant hematopoiesis. (<bold>A</bold>) <italic>Il7</italic>-GFP expression in mesenchymal stem cells (MSCs). (<bold>B</bold>) Number of non-malignant developing B cell subsets in bone marrow. (<bold>C</bold>) Neutrophil and monocyte numbers. (<bold>D</bold>) ALL cell number in bone marrow. (<bold>E–I</bold>) Comparison between control (PBS), IFNαR, and IFNγ blocking in ALL and non-malignant hematopoiesis. (<bold>E</bold>) <italic>Il7</italic>-GFP expression in MSCs. (<bold>F</bold>) Number of non-malignant developing B cell subsets in bone marrow. (<bold>G</bold>) Neutrophil and monocyte numbers. (<bold>H</bold>) Ter119+CD71+ immature RBC numbers. (<bold>I</bold>) ALL cell number in bone marrow. Mice transplanted with 3×10<sup>6</sup> BCR-ABL-expressing B-ALL cells and treated with the indicated reagents (150 µg/mouse) on day 0 and day 5; mice were analyzed on day 8. Bars indicate mean, circles depict individual mice. Data are representative of two independent experiments. *p&lt;0.05; **p&lt;0.005; ***p&lt;0.0005 unpaired, two-sided, Student’s <italic>t</italic> test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To test if LTβR signaling in MSCs impacts ALL growth, non-malignant hematopoiesis, and mouse survival, we transplanted ALL cells into mice conditionally deficient in <italic>Ltbr</italic> in MSCs (<italic>Ltbr<sup>fl/fl</sup>; Lepr<sup>Cre/+</sup></italic> mice, from here on referred as LTβR∆) that also report <italic>Il7</italic> transcription via GFP expression (<italic>Il7<sup>GFP/+</sup></italic>). We ruled out a role for LTβR signaling in MSCs in promoting ALL homing to the BM by transplanting 3×10<sup>6</sup> ALL cells into control or LTβR∆ mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), in agreement with prior studies showing that LTβR signaling in MSCs does not control CXCL12 expression under homeostatic conditions (<xref ref-type="bibr" rid="bib60">Zehentmeier et al., 2022</xref>). Transplanted ALL cells induced IL7 downregulation in control mice (WT, <italic>Lepr<sup>+/+</sup>; Ltbr<sup>fl/fl</sup></italic>) but not in LTβR∆ mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), as expected (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These changes in IL7 production corresponded with reduced lymphopoiesis in WT mice whereas lymphopoiesis was largely unaffected in LTβR∆ mice (<xref ref-type="fig" rid="fig4">Figure 4C–E</xref>). In contrast, ALL-induced reductions in myeloid and erythroid lineages were largely independent of LTβR signaling in MSCs (<xref ref-type="fig" rid="fig4">Figure 4G–J</xref>). The inability to induce LTβR signaling in MSCs also impacted ALL growth in vivo (<xref ref-type="fig" rid="fig4">Figure 4F and K</xref>) such that it extended mouse survival by approximately 1 week (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). To further test if ALL cells directly induce LTβR signaling in MSCs, we generated ALL cells genetically deficient in <italic>Ltb</italic> (<xref ref-type="fig" rid="fig4">Figure 4M</xref>). Indeed, <italic>Ltb</italic>-deficient ALL cells were unable to induce IL7 downregulation in MSCs and to block non-malignant lymphopoiesis (<xref ref-type="fig" rid="fig4">Figure 4N and O</xref>). Furthermore, <italic>Ltb</italic>-deficient ALL cells proliferated significantly less than <italic>Ltb</italic>-sufficient ALL cells (<xref ref-type="fig" rid="fig4">Figure 4P</xref>), which extended mouse survival significantly (<xref ref-type="fig" rid="fig4">Figure 4Q</xref>). Finally, to account for reduced <italic>Ltb</italic>-deficient ALL growth in vivo, we measured changes in <italic>Il7</italic> expression in mice transplanted with 3×10<sup>6</sup> <italic>Ltb</italic><sup>+/+</sup> ALLs, 3×10<sup>6</sup> <italic>Ltb</italic><sup>-/-</sup> ALLs, and 9×10<sup>6</sup> <italic>Ltb</italic><sup>-/-</sup> ALLs (3<italic>×Ltb</italic><sup>-/-</sup>). Importantly, IL7 expression was unchanged even in mice transplanted with threefold higher number of <italic>Ltb</italic>-deficient ALLs (<xref ref-type="fig" rid="fig4">Figure 4R and S</xref>). Combined, these studies show that the ALL-induced IL7 downregulation that we reported in previous studies (<xref ref-type="bibr" rid="bib22">Fistonich et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Zehentmeier and Pereira, 2019</xref>) is mediated by direct delivery of lymphotoxin ligands to LTβR expressed on BM MSCs.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Effects of mesenchymal stem cell (MSC)-intrinsic lymphotoxin beta receptor (LTβR) signaling in lymphopoiesis and B-ALL growth.</title><p>(<bold>A</bold>) Measurements of ALL homing to the bone marrow (BM): 3×10<sup>6</sup> BCR-ABL ALLs were transferred into control (red) or LTβR∆ (green) mice and allowed to home into the BM for 24 hr. (<bold>B</bold>) <italic>Il7</italic>-GFP expression in MSCs. (<bold>C–E</bold>) Number of non-malignant developing B cell subsets. (<bold>C</bold>) ProB cells. (<bold>D</bold>) Pre-B cells. (<bold>E</bold>) Immature B cells. (<bold>F</bold>) B-ALL frequency in BM. (<bold>G–K</bold>) Myeloid and erythroid cell numbers in BM. (<bold>G</bold>) Neutrophils. (<bold>H</bold>) Monocytes. (<bold>I</bold>) Immature RBCs. (<bold>J</bold>) Mature RBCs. (<bold>K</bold>) Total ALL number. (<bold>L</bold>) Probability of wild-type (WT) or LTβR∆ mouse survival after B-ALL transplantation (n=8 mice/group). Mice were transplanted with 3×10<sup>6</sup> BCR-ABL-expressing B-ALL cells and analyzed on day 8 after transplantation. (<bold>M</bold>) Histogram of LTβR ligand expression in ALL cells. Green, <italic>Ltb</italic>-sufficient; brown, <italic>Ltb</italic>-deficient. (<bold>N</bold>) <italic>Il7</italic>-GFP expression in MSCs. (<bold>O</bold>) Number of non-malignant developing B cell subsets. (<bold>P</bold>) ALL number. (<bold>Q</bold>) Frequency of WT mouse survival after <italic>Ltb</italic>-deficient or <italic>Ltb</italic>-sufficient ALL transplantation (n=7/group). (<bold>R and S</bold>) Effects of <italic>Ltb</italic>-expressing ALLs in MSCs. (<bold>R</bold>) <italic>Ltb<sup>+/+</sup></italic> and <italic>Ltb<sup>-/-</sup></italic> B-ALL numbers in BM 3 weeks after transplantation into <italic>Il7<sup>GFP/+</sup></italic> mice. (<bold>S</bold>) <italic>Il7</italic>-GFP expression in MSCs. Gray bar indicates control <italic>Il7<sup>GFP/+</sup></italic> mice (no ALL); green bar represents <italic>Il7<sup>GFP/+</sup></italic> mice recipient of 3×10<sup>6</sup> <italic>Ltb<sup>+/+</sup></italic> ALLs; brown bar indicates <italic>Il7<sup>GFP/+</sup></italic> mice recipient of 3×10<sup>6</sup> <italic>Ltb<sup>-/-</sup></italic> ALLs; red bars depict <italic>Il7<sup>GFP/+</sup></italic> mice recipient of 9×10<sup>6</sup> <italic>Ltb<sup>-/-</sup></italic> ALLs (3<italic>×Ltb<sup>-/-</sup></italic>). Bars indicate mean, circles depict individual mice. Data in all panels are representative of two independent experiments. *p&lt;0.05; **p&lt;0.005; ***p&lt;0.0005 unpaired, two-sided, Student’s <italic>t</italic> test. ALL, acute lymphoblastic leukemia.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Effects of IL7 administration in acute lymphoblastic leukemia (ALL) and non-leukemic lymphopoiesis in vivo.</title><p>(<bold>A</bold>) Experimental design of data described in panels B–C. Mice were transplanted with 3×10<sup>6</sup> ALLs and treated with IL7/aIL7 antibody complex (1.5 µg/15 µg, respectively) i.v. on days 6 and 7; mice were analyzed on day 9. (<bold>B</bold>) Number of non-malignant developing B cell subsets in bone marrow (BM). (<bold>C</bold>) Total ALL number in BM (left), spleen (middle), and B-ALL percentage in peripheral blood (right). Data are representative of two independent experiments. *p&lt;0.05; **p&lt;0.005; ***p&lt;0.0005 unpaired, two-sided, Student’s <italic>t</italic> test. #p&lt;0.05 Mann–Whitney test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To test if increased lymphopoiesis due to excess IL7 is directly responsible for reduced ALL growth in vivo, we treated mice transplanted with B-ALL cells with recombinant IL7 complexed with a neutralizing anti-IL7 (aIL7, clone M25) monoclonal antibody (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), which increases the half-life of recombinant IL-7 in vivo (<xref ref-type="bibr" rid="bib7">Boyman et al., 2008</xref>). Indeed, mice treated with IL7/aIL7 had significantly higher numbers of developing B cell subsets in the BM (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), particularly of IL7-dependent proB and pre-B cells. Conversely, ALL numbers in BM were significantly reduced, which reflected in significant reductions in peripheral blood and spleen (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Combined, these data demonstrate that the lymphotoxin-mediated attenuation of IL7 production reduces lymphopoiesis, which results in accelerated ALL growth.</p><p>Sleckman and colleagues used an elegant mouse model consisting of Artemis-deficient mice crossed with immunoglobulin heavy chain transgenic mice (Vh147) and with EµBCL2 transgenic mice to study the impact of double stranded DNA break (DSB) repair pathway in B cell development. In these studies, they reported NFκB activation in pre-BCR-expressing pre-B cells that could not repair DSBs due to deficiency in Artemis (<xref ref-type="bibr" rid="bib8">Bredemeyer et al., 2008</xref>; <xref ref-type="bibr" rid="bib6">Bednarski et al., 2016</xref>). In previous studies using this model, we showed that Artemis-deficient pre-B cells could also induce IL7-downregulation in MSCs (<xref ref-type="bibr" rid="bib22">Fistonich et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Zehentmeier and Pereira, 2019</xref>), suggesting that the LTβR pathway may also be engaged in pre-leukemic states. Consistent with this possibility, when comparing the transcriptome of Artemis-deficient (<italic>Dclre1c</italic><sup>−/−</sup>) and Rag1-deficient (<italic>Rag1<sup>−/−</sup></italic>) pre-B cells, we noted that Artemis-deficient pre-B cells also expressed significantly higher amounts of LTα and LTβ transcripts (<xref ref-type="bibr" rid="bib8">Bredemeyer et al., 2008</xref>; <xref ref-type="bibr" rid="bib6">Bednarski et al., 2016</xref>). In agreement with these observations, we detected higher amounts of LTα and LTβ protein on the cell surface of <italic>Dclre1c</italic><sup>−/−</sup> pre-B cells than on <italic>Rag1<sup>−/−</sup></italic> pre-B cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Transplantation of <italic>Dclre1c</italic><sup>−/−</sup> BM cells into lethally irradiated <italic>Il7<sup>GFP/+</sup></italic> LTβR∆ mice or control littermate revealed LTβR-dependent <italic>Il7</italic> downregulation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), which resulted in a trend towards increased numbers of Artemis-deficient B cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). In contrast, Artemis deficiency did not impact myeloid-erythroid production (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D and E</xref>). Artemis deficiency renders cells unable to repair DSBs which causes a supraphysiological activation of the DNA damage response pathway (<xref ref-type="bibr" rid="bib5">Bednarski and Sleckman, 2012</xref>). To test if the DNA damage response controls LTα and LTβ expression, we treated ALL cells with Etoposide, a chemotherapeutic agent that prevents DSB repair. ALLs upregulated LTα on the cell surface in an Etoposide dose-response manner (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F and G</xref>). The DNA damage response pathway signals activation of NFκB. Interestingly, treatment with IMD0354 (a small molecule inhibitor of IKKβ-mediated IκB phosphorylation) significantly reduced lymphotoxin α1β2 expression in Etoposide-treated ALLs (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1H</xref>). Combined, these studies demonstrate that LTα and LTβ expression can be activated by DNA damage response pathway.</p></sec><sec id="s2-3"><title>CXCR4 signaling potentiates ALL lethality</title><p>Prior studies have shown that Gαi-protein coupled receptor signaling in B-lineage cells promotes lymphotoxin α1β2 expression (<xref ref-type="bibr" rid="bib2">Ansel et al., 2000</xref>). Engagement of LTβR expressed on secondary lymphoid organ stromal cells increases the production of B cell chemokines, which further increases lymphotoxin α1β2 expression in B cells, thus establishing a feedforward loop (<xref ref-type="bibr" rid="bib2">Ansel et al., 2000</xref>; <xref ref-type="bibr" rid="bib18">Cyster et al., 2000</xref>). To test if CXCR4 signaling in ALLs promotes lymphotoxin α1β2 expression, we treated ALLs in vitro with a range of CXCL12 concentrations and measured surface LTα. Indeed, ALLs upregulated LTα after exposure to CXCL12 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Furthermore, LTα expression was further increased in ALLs treated with CXCL12 and Etoposide (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Although prior studies have also shown that IL7R signaling can promote lymphotoxin α1β2 expression in lymphoid tissue inducer cells (<xref ref-type="bibr" rid="bib58">Yoshida et al., 2002</xref>), in ALL cells IL7R signaling was not sufficient for upregulating surface LTα even at high IL7 concentrations, even though it promoted IL7Ra internalization (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A and B</xref>). To test if CXCR4 signaling is required for lymphotoxin α1β2 expression in ALLs in vivo, we transplanted 3×10<sup>6</sup> ALL cells into WT mice for 1 week and treated them with AMD3100, or saline, 12 hr prior to sacrifice. Indeed, lymphotoxin α1β2 expression was significantly reduced in ALLs and in non-leukemic pre-B cells of AMD3100-treated mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Conversely, AMD3100 increased CXCR4 surface expression in ALL and non-leukemic pre-B cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), as expected (<xref ref-type="bibr" rid="bib11">Broxmeyer et al., 2005</xref>; <xref ref-type="bibr" rid="bib4">Beck et al., 2014</xref>). AMD3100 has a short half-life in vivo thus making it unsuitable for long-term treatment in vivo (<xref ref-type="bibr" rid="bib4">Beck et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Hendrix et al., 2000</xref>). To test if CXCR4 antagonism also prevents ALL-induced IL7 downregulation in BM MSCs, we transferred 3×10<sup>6</sup> ALL cells into <italic>Il7<sup>GFP/+</sup></italic> mice and treated them with an orally bioavailable CXCR4 antagonist (<xref ref-type="bibr" rid="bib19">Dale et al., 2020</xref>) or with vehicle by daily gavage (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). While control-treated mice showed ALL-induced <italic>Il7</italic>-GFP downregulation in MSCs, mice treated with CXCR4 antagonist maintained IL7 expression within the normal range of mice without ALL (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Similarly, developing B cells were significantly reduced in control-treated mice, but their numbers were normal in CXCR4 antagonist treated mice (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). In contrast, ALL numbers were significantly decreased in the BM and periphery of mice treated with CXCR4 antagonist (<xref ref-type="fig" rid="fig5">Figure 5H</xref>), which correlated with extended mouse survival (<xref ref-type="fig" rid="fig5">Figure 5I</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>CXCR4 signaling and its impact on acute lymphoblastic leukemia (ALL) growth in vivo.</title><p>(<bold>A</bold>) Histograms of LTα expression in B-ALL cells treated for 16 hr with CXCL12 at the indicated concentrations in vitro. (<bold>B</bold>) Histograms of LTα expression and geometric mean intensity (plotted as percent of untreated cells) in B-ALL cells treated with Etoposide (ETP, 1 µM) alone or in combination with CXCL12 (500 ng/mL) in vitro. (<bold>C and D</bold>) LTα (<bold>C</bold>) and CXCR4 expression (<bold>D</bold>) in ALLs and non-leukemic pre-B cells in the bone marrow (BM) of mice transplanted with 3×10<sup>6</sup> <italic>Ltb<sup>+/+</sup></italic> BCR ABL ALLs. ALLs were allowed to expand in vivo for 7 days. Mice were treated with saline or AMD3100 (80 µg/mouse/i.v.) 18 hr prior to sacrifice. (<bold>E</bold>) Experimental design of data described in panels F–H. Mice were transplanted with 3×10<sup>6</sup> BCR-ABL-expressing B-ALL cells and treated daily with CXCR4 antagonist starting on day 2 and until day 7; mice were analyzed on day 8. (<bold>F</bold>) <italic>Il7</italic>-GFP expression in mesenchymal stem cells (MSCs). (<bold>G</bold>) Number of non-malignant developing B cell subsets. (<bold>H</bold>) Total ALL number in BM (left), spleen (middle), and B-ALL percentage in peripheral blood (right). (<bold>I</bold>) Frequency of mouse survival after B-ALL transplantation into mice treated with vehicle or CXCR4 antagonist (n=13/group). (<bold>J</bold>) CXCR4 expression on developing B cells and ALLs in BM. (<bold>K</bold>) In vitro chemotaxis of developing B cells and ALLs. Data in panels J and K are from BM of mice 1 week after ALL transplantation. Data are representative of two independent experiments. *p&lt;0.05; **p&lt;0.005; ***p&lt;0.0005 unpaired, two-sided, Student’s <italic>t</italic> test. #p&lt;0.05 Mann–Whitney test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Regulation of Lymphotoxin α1β2 expression by the DNA damage response pathway.</title><p>(<bold>A</bold>) Lethally irradiated wild-type (WT) mice were reconstituted with <italic>Rag1</italic>-deficient <italic>Igh</italic>-tg (red) or Artemis (<italic>Dclrec1</italic>)-deficient <italic>Igh</italic>-tg bone marrow. Histograms of LTα and LTβ expression in <italic>Rag1</italic>-deficient <italic>Igh</italic>-tg pre-B (red) and Artemis (<italic>Dclrec1</italic>)-deficient <italic>Igh</italic>-tg pre-B cells (blue). (<bold>B–E</bold>) Lethally irradiated <italic>Il7<sup>GFP/+</sup> LeprCre<sup>Cre/+</sup> Ltbrfl<sup>fl/fl</sup></italic> (green) and <italic>Il7<sup>GFP/+</sup> Lepr<sup>+/+</sup> Ltbrfl<sup>fl/fl</sup></italic> (gray) mice were reconstituted with bone marrow from Artemis (<italic>Dclrec1</italic>)-deficient <italic>Igh</italic>-tg mice. (<bold>B</bold>) <italic>Il7</italic>-GFP expression in MSCs. (<bold>C</bold>) Developing B cell numbers in bone marrow. (<bold>D</bold>) Neutrophil and monocyte numbers. (<bold>E</bold>) Ter119+CD71+ immature RBC numbers. Bars indicate mean, circles depict individual mice. (<bold>F</bold>) Histograms of LTα expression in B-ALL cells treated with Etoposide (ETP) at the indicated concentrations in vitro. (<bold>G</bold>) LTα geometric mean fluorescence in cells described in panel F plotted as percent of untreated cells. (<bold>H</bold>) Geo. mean intensity of LTα expression in acute lymphoblastic leukemias (ALLs) treated in vitro with and without Etoposide and IKKβ inhibitor IMD 3504 for 16 hr. Data are representative of two independent experiments. *p&lt;0.05; **p&lt;0.005; unpaired, two-sided, Student’s <italic>t</italic> test; panel H column A versus B Mann–Whitney test; #p&lt;0.05; ####p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Effects of IL7 on lymphotoxin α1β2 expression.</title><p>(<bold>A</bold>) LTa expression on acute lymphoblastic leukemias (ALLs) treated with IL7 in vitro for 24 hr measured by flow cytometry. (<bold>B</bold>) IL7Ra expression on ALLs treated with IL7 in vitro for 24 hr measured by flow cytometry.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig5-figsupp2-v2.tif"/></fig></fig-group><p>Several studies have demonstrated that CXCR4 promotes ALL homing and retention in the BM (<xref ref-type="bibr" rid="bib29">Juarez et al., 2007</xref>; <xref ref-type="bibr" rid="bib48">Sipkins et al., 2005</xref>). Paradoxically, our studies revealed that ALLs induce a small, but significant, downregulation of CXCL12 expression in vivo (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). However, when comparing CXCR4 protein levels between ALLs and non-leukemic B cell progenitors developing in the same microenvironment, we noted that ALLs express significantly higher amounts of CXCR4 in vivo (<xref ref-type="fig" rid="fig5">Figure 5J</xref>) and migrate towards a CXCL12 gradient in vitro significantly more than non-leukemic developing B cell subsets (<xref ref-type="fig" rid="fig5">Figure 5K</xref>). These observations suggest that ALLs are retained more efficiently in the BM than non-leukemic B cell progenitors.</p></sec><sec id="s2-4"><title>LTβR signaling promotes AML growth and lethality</title><p>As previously mentioned, AML also induces the downregulation of multiple hematopoietic cytokines expressed by MSCs, including IL7 (<xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>). Furthermore, we also found an inverse correlation between <italic>LTB</italic> transcript abundance and patient outcome in a cohort of AML patients from the Cancer Genome Atlas (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). To study the impact of AML growth in non-malignant hematopoiesis, we used a doxycycline (DOX)-inducible mouse model of the MLL-AF9 oncogenic fusion driving AML (<xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>). In a mixed BM chimera of DOX-induced MLL-AF9 transgenic and competitor WT cells expressing CD45.1, MLL-AF9 expression increased the frequency of AML cells and of myeloid cell subsets expressing NGFR, a reporter for MLL-AF9 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref>). In contrast, both erythroid and lymphoid subsets were significantly reduced 2 and 4 weeks after MLL-AF9 induction (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D and E</xref>). Next, we tested if the LTβR pathway is also engaged by AMLs. LTβ expression is higher on MLL-AF9-positive than on MLL-AF9-negative myeloid cells and neutrophils (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). MLL-AF9-expressing cells induced IL7 downregulation in MSCs, which could be blocked with LTβR-Ig but not with Hel-Ig treatment (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The effect of LTβR-Ig treatment also restored B lymphopoiesis partially (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), but not erythropoiesis (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), which correlated with reduced AML growth in vivo and extended mouse survival (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>). Similar findings were obtained with AML cells deficient in <italic>Ltb</italic> (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Overall, these studies collectively demonstrate that acute lymphoid and myeloid leukemias turn off lymphopoiesis by expressing LTβR ligands and downregulating IL7 production.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Lymphotoxin α1β2 expression in acute myeloblastic leukemias (AMLs) and therapeutic effect of lymphotoxin beta receptor (LTβR) blocking.</title><p>(<bold>A</bold>) Histograms of LTβ expression in AML cells (NGFR+, red), in non-malignant myeloid cells (NGFR-, blue) and in non-malignant neutrophils (Net., black). (<bold>B</bold>) <italic>Il7</italic>-GFP expression in mesenchymal stem cells (MSCs). (<bold>C</bold>) Number of non-malignant developing B cell subsets in bone marrow. (<bold>D</bold>) Ter119+ red blood cell number. (<bold>E</bold>) AML cell number in bone marrow. (<bold>F</bold>) Probability of mouse survival after AML transplantation following pre-treatment with either HEL-Ig or LTβR-Ig (n=5 per group). (<bold>G</bold>) Probability of mouse survival after <italic>Ltb</italic>-deficient or sufficient AML transplantation (n=10 per group). In panels B–G, comparisons between control (no AML, gray), AML treated with Hel-Ig (peach gray), and AML treated with LTβR-Ig (wine red). Bars indicate mean, circles depict individual mice. Data are representative of two independent experiments. *p&lt;0.05; ***p&lt;0.0005 unpaired, two-sided, Student’s <italic>t</italic> test. #p&lt;0.05 Mann–Whitney test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Kinetics of acute myeloblastic leukemia (AML) growth and disruption of non-malignant hematopoiesis.</title><p>(<bold>A</bold>) mRNA levels of <italic>LTB</italic> were analyzed in microarray datasets (COG P9906) and associated with clinical outcome. Patients in each group were segregated into higher- versus lower-than-median <italic>LTB</italic> mRNA levels. Kaplan–Meier plot shows relapse-free survival probability. Mantel–Cox log-rank tests (two-sided) were used to determine statistical significance. Y-axes indicate time in years. (<bold>B</bold>) Frequency of NGFR+AMLs in bone marrow 4 weeks after MLL-AF9 induction. (<bold>C–E</bold>) Changes in bone marrow hematopoiesis during AML growth. (<bold>C</bold>) Granulocyte/monocyte progenitors, monocytes, and neutrophils. (<bold>D</bold>) Ter119+CD71+ immature red blood cells. (<bold>E</bold>) Number of non-malignant developing B cell subsets in bone marrow. In panels C–E, X-axis indicates time in weeks. Bars indicate mean, circles depict individual mice. Data are representative of two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83533-fig6-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Like normal hematopoietic progenitors, leukemia cells physically interact with the BM niche and deliver signals capable of re-programming MSCs and ECs and altering the hematopoietic output (<xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>; <xref ref-type="bibr" rid="bib50">Tikhonova et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Fistonich et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Zehentmeier and Pereira, 2019</xref>; <xref ref-type="bibr" rid="bib37">Méndez-Ferrer et al., 2020</xref>). In this study, we showed that lymphotoxin α1β2 delivered by ALL and AML cells to LTβR expressed on MSCs is one mechanism by which leukemic cells dysregulate MSCs and alter hematopoiesis. The fact that AML and ALL cells physically interact with MSCs provides opportunities for LTβR engagement via membrane-bound lymphotoxin ligands.</p><p>Previously, we uncovered cell circuits between Artemis-deficient pre-B cells and IL7-producing MSCs that resulted in IL7 downregulation (<xref ref-type="bibr" rid="bib22">Fistonich et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Zehentmeier and Pereira, 2019</xref>). Here, we demonstrated that the Artemis-deficient pre-B cells express elevated lymphotoxin α1β2 and that IL7 downregulation was dependent on LTβR signaling in MSCs. These findings identify the DSB sensing and repair pathway as one mechanism promoting lymphotoxin α1β2 expression in pre-leukemic cells through the activation of NFκB transcriptional activity. Because upregulation of lymphotoxin α1β2 in pre-B cells carrying unrepaired DSBs promotes IL7 downregulation, we speculate that this mechanism may contribute to the efficient elimination of pre-leukemic B cell progenitors in vivo. Whether the same mechanism is responsible for lymphotoxin α1β2 upregulation in AML cells remains to be determined.</p><p>Besides the DSB pathway, chemokine receptor signaling, particularly CXCR5 and CXCR4, have also been shown to promote lymphotoxin α1β2 expression in B-lineage cells (<xref ref-type="bibr" rid="bib2">Ansel et al., 2000</xref>). Our studies revealed that CXCR4 signaling also induces lymphotoxin α1β2 expression in ALL cells in vitro and in vivo. CXCL12 is the most abundant chemokine expressed by MSCs and ECs in BM, and CXCR4 expression levels in AML and ALL cells inversely correlate with patient outcome (<xref ref-type="bibr" rid="bib12">Cancilla et al., 2020</xref>). We suggest that CXCR4 signaling not only enables leukemic cell interactions and delivery of lymphotoxin α1β2 to MSCs but also promote further lymphotoxin α1β2 expression in leukemic cells in a feed-forward loop that shuts down IL7 expression and blocks lymphopoiesis. The fact that our studies also revealed an inverse correlation between lymphotoxin α1β2 expression and ALL and AML patient outcome, as has been described with CXCR4 (<xref ref-type="bibr" rid="bib12">Cancilla et al., 2020</xref>), is in agreement with the data presented in this study showing that CXCR4 and LTβR act in the same axis.</p><p>Prior studies using mouse models of AML have shown that CXCL12 is downregulated in MSCs when AML develops (<xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>). Here, we showed that ALL cells induce a small but significant downregulation of CXCL12 expression in MSCs that is partly dependent on LTβR signaling. However, despite the CXCL12 downregulation, ALL cells are still retained in the BM presumably due to higher CXCR4 expression when compared to that observed in non-leukemic large cycling pre-B cells. We speculate that high CXCR4 levels confer competitive advantage over non-leukemic hematopoietic progenitors in BM retention and access to supportive microenvironments for cell growth.</p><p>Studies using cell-based therapies with T cells expressing anti-CD19 chimeric antigen receptors (CAR-T cells) have shown promising therapeutic effects against B cell malignancies (<xref ref-type="bibr" rid="bib33">Kochenderfer et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Kalos et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Porter et al., 2011</xref>). Although remission has been achieved in some patients (<xref ref-type="bibr" rid="bib25">Grupp et al., 2013</xref>; <xref ref-type="bibr" rid="bib36">Maude et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">Porter et al., 2015</xref>), many patients still relapse due to a variety of reasons including defects in long-term persistence of CAR-T cells (<xref ref-type="bibr" rid="bib47">Shah and Fry, 2019</xref>). A recent study, however, showed that CAR-T engineered to express IL7 improved their long-term persistence (<xref ref-type="bibr" rid="bib1">Adachi et al., 2018</xref>). It is possible that LTβR blocking in combination with CAR-T cell therapy particularly for B cell leukemias may also improve CAR-T cell persistence by increasing IL7 production in BM while not affecting CXCL12 expression.</p><p>In this study, we showed that ALL cells enforce the downregulation of several myeloid and lymphoid cytokines produced by MSCs and ECs. These findings are reminiscent of prior observations made with mouse models of AML (<xref ref-type="bibr" rid="bib3">Baryawno et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Hanoun et al., 2014</xref>). Of all hematopoietic cytokines downregulated by leukemic cells, only IL7 (and partly CXCL12) are regulated by LTβR signaling. Other cytokines, such as SCF (encoded by <italic>Kitl</italic>), M-CSF (encoded by <italic>Csf1</italic>), IL34, FLT3L, etc., are also downregulated but in an LTβR-independent manner. Of note, SCF is a critical cytokine for the survival and expansion of myelo-erythroid lineage progenitors (<xref ref-type="bibr" rid="bib38">Miao et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Broudy et al., 1995</xref>; <xref ref-type="bibr" rid="bib10">Broudy, 1997</xref>; <xref ref-type="bibr" rid="bib41">Munugalavadla and Kapur, 2005</xref>), and its consumption in vivo is under competition between hematopoietic stem and progenitor cells (<xref ref-type="bibr" rid="bib39">Miao et al., 2022</xref>). The fact that SCF production is insensitive to LTβR signaling may contribute to explain why myelopoiesis and erythropoiesis are not restored when LTβR signaling is blocked. These findings also raise the possibility that additional receptor(s)/ligand(s) interaction(s) are responsible for controlling the production of other hematopoietic cytokines. Further studies are needed to identify additional pathways responsible for MSC and EC re-programming in response to leukemias.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Mice</title><p>C57BL/6NCR (strain code 556, CD45.2+) and B6-Ly5.1/Cr (stain code 564, CD45.1+) were purchased from Charles River Laboratories. <italic>Lepr</italic>-cre mice were purchased from The Jackson Laboratories. <italic>Il7<sup>GFP/+</sup></italic> mice were from our internal colony. <italic>Ltb<sup>fl/fl</sup></italic> (<xref ref-type="bibr" rid="bib51">Tumanov et al., 2002</xref>) and <italic>Ltbr<sup>fl/fl</sup></italic> (<xref ref-type="bibr" rid="bib56">Wang et al., 2010</xref>) mice were bred at Yale Animal Resources Center. DOX-inducible MLL-AF9 (<italic>Hprt<sup>MLL-AF9</sup>, Rosa26<sup>rtTA/rtTA</sup></italic>) transgenic mice were bred at Yale University. Male and female adult mice (8–12 weeks) were used for all experiments. All mice were maintained under specific pathogen-free conditions at the Yale Animal Resources Center and were used according to the protocol approved by the Yale University Institutional Animal Care and Use Committee (2022-11377).</p></sec><sec id="s4-2"><title>Adoptive transfer of BCR-ABL-expressing B-ALL cells and in vivo cytokine/cytokine receptor blocking</title><p>BCR-ABL-expressing B-ALL cells are developmentally arrested at the pre-B cell stage (kindly provided by Hilde Schjerven, UCSF). B-ALL cells were injected into recipient mice by tail vein, and then analyzed at different time points. For cytokine/cytokine receptor blocking, 150 μg of LTβR-Ig/HEL-Ig (Biogen), anti-TNF antibody (Bio-X-Cell #BE0058), anti-mouse IL1b (Bio-X-Cell #BE0246), anti-mouse IFNAR1 (Bio-X-Cell #BE0241), or anti-mouse IFNγ (Bio-X-Cell #BE BE0055) were injected intravenously via retro-orbital sinus immediately prior to ALL cell injection (tail vein). Then antibody treatment was administered every 5 days with same amount.</p></sec><sec id="s4-3"><title>Flow cytometry</title><p>BM MSCs were isolated as previously described (<xref ref-type="bibr" rid="bib17">Cordeiro Gomes et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Zehentmeier et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Lim et al., 2023</xref>). Briefly, long bones were flushed with HBSS supplemented with 2% of heat-inactivated fetal bovine serum, penicillin/streptomycin, L-glutamine, HEPES, and 200 U/mL Collagenase IV (Worthington Biochemical Corporation) and digested for 30 min at 37°C. Cells were filtered through a 100 μm nylon mesh and washed with HBSS/2% FBS. All centrifugation steps were done at 1200 rpm for 5 min and all stains were done on ice. LEPR stains were done for 1 hr and all other stains for 20 min on ice. BM MSCs were identified as CD45<sup>-</sup> Ter119<sup>-</sup> CD31<sup>-</sup> CD144<sup>-</sup> LEPR<sup>+</sup> cells. For analysis of hematopoietic populations, long bones were flushed with DMEM supplemented with 2% fetal calf serum, penicillin/streptomycin, L-glutamine, and HEPES. Red blood cells were lysed with ammonium chloride buffer.</p><p>Hematopoietic cell populations were identified as follows: proB: CD19<sup>+</sup> CD93<sup>+</sup> IgM<sup>-</sup> cKit<sup>+</sup>; pre-B: CD19<sup>+</sup> CD93<sup>+</sup> IgM<sup>-</sup> cKit<sup>-</sup>; immature B: CD19<sup>+</sup> IgM<sup>+</sup> CD93<sup>+</sup>; mature B: CD19<sup>+</sup> IgM<sup>+</sup> CD93<sup>-</sup>; immature neutrophils: CD115<sup>-</sup> Gr1<sup>+</sup> CD11b<sup>hi</sup> CXCR4<sup>hi</sup>; mature neutrophils: CD115<sup>-</sup> Gr1<sup>hi</sup> CD11b<sup>lo</sup>; immature monocytes: CD115<sup>+</sup> Gr1<sup>+</sup> CXCR4<sup>hi</sup>; mature monocytes: CD115<sup>+</sup> Gr1<sup>+</sup> CXCR4<sup>lo</sup>; GMP: Lineage<sup>-</sup> cKit<sup>+</sup> SCA-1<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>hi</sup>; immature and mature erythrocytes: Ter119<sup>+</sup> CD71<sup>-</sup> (mature) or CD71<sup>+</sup> (mature). The lineage cocktail was as follows: CD19, B220, CD3e, CD4, Gr1, NK1.1, Ter119, CD11b, and CD11c.</p><p>Measurements of LTα and LTβ expression were performed using anti-mouse LTα and LTβ antibodies (a gift from Biogen). A list of antibodies and conditions used is provided in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-4"><title>Generation of <italic>Ltb</italic>-deficient BCR-ABL B-ALL cells</title><p>YFP tagged BCR-ABL plasmid was kindly provided by Dr Hilde Schjerven (UCSF). Pre-B cells were sorted <italic>from Ltb<sup>+/-</sup></italic>or <italic>Ltb<sup>-/-</sup></italic> mouse BM by gating on CD19+CD93+IgM-cKit-. Sorted pre-B cells were transduced with BCR-ABL YFP retroviruses. After infection, pre-B cells were cultured in DMEM supplemented with 20% FBS, penicillin/streptomycin, L-glutamine, HEPES, 0.05 mM 2-mercaptoethanol, and 100 ng/mL recombinant murine IL7 (peprotech, 217-17). After 2 days of culture, cells were cultured in the same media without IL7 and expanded for transplantation. Recipient mice received 6 Gy gamma irradiation before transplantation.</p></sec><sec id="s4-5"><title>Induction of AML in vivo</title><p>MLL-AF9 mice were maintained and genotyped as previously described (<xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>). Two million BM cells recovered from MLL-AF9 transgenic mice were mixed with 1 million BM cells from WT congenic CD45.1 mice; BM mixtures were transplanted into lethally irradiated CD45.1 recipients. Two weeks after transplantation, mice were fed with 1 g/L Dox in the drinking water sweetened with 10 g/L sucrose. For <italic>Ltb</italic>-deficient MLL-AF9 experiment, <italic>Ltb<sup>-/-</sup></italic> mice were crossed with MLL-AF9 transgenic mice to generate <italic>Ltb<sup>+/-</sup>,</italic> MLL-AF9 and <italic>Ltb<sup>-/-</sup>,</italic> MLL-AF9 mice.</p></sec><sec id="s4-6"><title>Treatments with CXCR4 antagonists</title><p>CXCR4 receptor antagonist X4P-X4-185-P1 (X4 Pharmaceuticals) was dissolved in 50 mM citrate buffer, pH 4.0. Mice were treated at 100 mg/kg daily by oral gavage 2 days after ALL adoptive transfer. Control mice were treated by oral gavage of citrate buffer alone. Some experiments were performed with the CXCR4 antagonist AMD3100 (Sigma). Briefly, mice were transplanted with 3×10<sup>6</sup> ALL cells i.v. (tail vein) and ALLs were allowed to expand in vivo for 7 days. Mice were treated every 6 hr with 80 µg AMD3100 dissolved in saline (200 µL/mouse) i.v. for a period of 18 hr prior to sacrifice.</p></sec><sec id="s4-7"><title>IL7 treatment in vivo</title><p>Recombinant murine IL7 of 1.5 µg (peprotech, 217-17) was pre-incubated with 15 µg IL7 antibody (clone M25, Bio-X-Cell) for 20 min at room temperature. Mice were treated i.v. with IL7/aIL7 complex on day 6 and seven after adoptive transfer of BCR-ABL-expressing B-ALL cells. Mice were analyzed 48 hr after the last IL7/aIL7 treatment.</p></sec><sec id="s4-8"><title>In vitro studies with BCR-ABL-expressing B-ALL cells</title><sec id="s4-8-1"><title>Role of CXCR4 signaling in lymphotoxin α1β2 expression</title><p>One million ALL cells were incubated with 100, 200, 300, or 500 ng/mL CXCL12 (R&amp;D, 460-SD-050) for 16 hr, then stained with anti-mouse LTα antibody (a gift from Biogen) and analyzed by flow cytometry.</p></sec><sec id="s4-8-2"><title>Role of DNA damage repair pathway in lymphotoxin α1β2 expression</title><p>Etoposide treatment: One million ALL cells were incubated with 0.01, 0.1, 0.5, 1, 2, 5, 15, 50 µM Etoposide for 16 hr before analyzing LTα expression by flow cytometry.</p></sec><sec id="s4-8-3"><title>Role of NFκB signaling in lymphotoxin α1β2 expression</title><p>IMD 3504 (Abcam, Ab144823) was dissolved in DMSO, and dilutions prepared in saline. One million ALL cells were incubated with Etoposide for 16 hr in the presence of carrier or IMD 3504 at the indicated concentrations. Cells were stained and analyzed for LTα expression by flow cytometry.</p></sec></sec><sec id="s4-9"><title>MSC sorting and RNA-sequencing</title><p>BM stromal cells were isolated as previously described (<xref ref-type="bibr" rid="bib17">Cordeiro Gomes et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Zehentmeier et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Lim et al., 2023</xref>). Briefly, hematopoietic cells were depleted by staining with biotin-conjugated CD45 and Ter119 antibodies followed by magnetic depletion with Dynabeads Biotin Binder (Invitrogen #11047). Remaining cells were stained with antibodies against CD31, CD144, and PDGFRα, and MSCs were sorted as CD45<sup>-</sup> Ter119<sup>-</sup> CD31<sup>-</sup> CD144<sup>-</sup> PDGFRα<sup>+</sup> cells using a BD FACS Aria II. Cells were sorted directly into 350 μL RLT plus buffer (Qiagen) and RNA extracted using the RNeasy Plus Micro Kit (Qiagen #74034). RNA-sequencing was performed by the Yale Center for Genome Analysis using the Illumina HiSeq2500 system, with paired-end 75 bp read length. The sequencing reads were aligned onto <italic>Mus musculus</italic> GRCm38/mm10 reference genome, using the HISAT2 software. The mapped reads were converted into the count matrix with default parameters using the StringTie2 software, followed by the variance stabilizing transformation offered by DESeq2. DEGs were identified using the same software, DESeq2, based on a negative binomial generalized linear models and visualized in hierarchically clustered heatmaps using the pheatmap R package.</p></sec><sec id="s4-10"><title>Statistical analyses</title><p>We used Student’s <italic>t</italic> test to determine if differences between experimental grous with normal distribution were statistically significant. Shapiro–Wilk normality test was performed to assess distribution normality (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). We employed a non-parametric Mann–Whitney test for experimental groups with abnormal distribution. Differences in mouse survival between experimental groups were analyzed by the Kaplan–Meyer method.</p></sec><sec id="s4-11"><title>Patient outcome and gene expression microarray data</title><p>The B-ALL gene expression microarray and patient outcome data were obtained from the National Cancer Institute TARGET Data Matrix (<ext-link ext-link-type="uri" xlink:href="http://targetnci.nih.gov/dataMatrix/TARGET_DataMatrix.html">http://targetnci.nih.gov/dataMatrix/TARGET_DataMatrix.html</ext-link>) of the Children’s Oncology Group (COG) Clinical Trial P9906 with the GEO database accession number GSE11877 (<xref ref-type="bibr" rid="bib31">Kang et al., 2010</xref>). The patients were segregated into two groups according whether they had above or below the median expression level of a gene (i.e., the average of multiple probesets for a gene) or above the top 25% or below the bottom 25% expression level of a gene. OS or RFS probabilities were estimated using the Kaplan–Meier method, and log-rank test (two-sided) was used to compare survival differences between the two patient groups. R package ‘survival’ version 2.35-8 was used for the survival analysis.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Software, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Software</p></fn><fn fn-type="con" id="con7"><p>Resources, Software, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Software, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Funding acquisition, Investigation, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All mice were maintained under specific pathogen-free conditions at the Yale Animal Resources Center and were used according to the protocol approved by the Yale University Institutional Animal Care and Use Committee. (2022-11377).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Acute lymphoblastic leukemia (ALL)-induced gene expression changes in Lepr+ mesenchymal stem cells (MSCs).</title><p>Differentially expressed genes analyzed by bulk RNA-sequencing of Lepr+ MSPCs isolated from resting wild-type (WT) mice or Hel-Ig treated WT mice transplanted with ALL cells for 2 weeks. Related to <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p></caption><media xlink:href="elife-83533-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Lymphotoxin beta receptor (LTβR)-regulated genes in Lepr+ MSPCs during acute lymphoblastic leukemia (ALL) progression.</title><p>Differentially expressed genes analyzed by bulk RNA-sequencing of Lepr+ MSPCs isolated from ALL transplanted wild-type mice treated with control or LTβR-Ig (100 µg/mouse/week) for 2 weeks. Related to <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p></caption><media xlink:href="elife-83533-supp2-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of antibodies used in this study.</title></caption><media xlink:href="elife-83533-supp3-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Shapiro–Wilk normality test of the experimental groups examined.</title></caption><media xlink:href="elife-83533-supp4-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83533-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Accession number to RNA expression data were deposited in NCBI (GSE221243).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Geng</surname><given-names>H</given-names></name><name><surname>Müschen</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin-beta receptor signaling</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE218505">GSE218505</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr Alexei Tumanov (UT San Antonio) for providing <italic>Ltb</italic> and <italic>Ltbr</italic> floxed mouse strains; Dr Hilde Schjerven for providing BCR-ABL1 B-ALL cells and BCR-ABL1 retroviral expression plasmid. We thank Dr Art Taveras (X4 Pharmaceuticals) for providing CXCR4 antagonist. We thank Dr Linda Burkly (Biogen) for providing LTα and LTβ antibodies, LTβR-Ig and Hel-Ig. These studies were funded by the NIH (R01AI113040, R21AI133060, R35CA197628, R01AI164692, and R21AI146648). XF was funded by the NIH (T32 DK007356).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>K</given-names></name><name><surname>Kano</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Okuyama</surname><given-names>N</given-names></name><name><surname>Sakoda</surname><given-names>Y</given-names></name><name><surname>Tamada</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Il-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor</article-title><source>Nature Biotechnology</source><volume>36</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1038/nbt.4086</pub-id><pub-id pub-id-type="pmid">29505028</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansel</surname><given-names>KM</given-names></name><name><surname>Ngo</surname><given-names>VN</given-names></name><name><surname>Hyman</surname><given-names>PL</given-names></name><name><surname>Luther</surname><given-names>SA</given-names></name><name><surname>Förster</surname><given-names>R</given-names></name><name><surname>Sedgwick</surname><given-names>JD</given-names></name><name><surname>Browning</surname><given-names>JL</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A chemokine-driven positive feedback loop organizes lymphoid follicles</article-title><source>Nature</source><volume>406</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/35018581</pub-id><pub-id pub-id-type="pmid">10917533</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baryawno</surname><given-names>N</given-names></name><name><surname>Przybylski</surname><given-names>D</given-names></name><name><surname>Kowalczyk</surname><given-names>MS</given-names></name><name><surname>Kfoury</surname><given-names>Y</given-names></name><name><surname>Severe</surname><given-names>N</given-names></name><name><surname>Gustafsson</surname><given-names>K</given-names></name><name><surname>Kokkaliaris</surname><given-names>KD</given-names></name><name><surname>Mercier</surname><given-names>F</given-names></name><name><surname>Tabaka</surname><given-names>M</given-names></name><name><surname>Hofree</surname><given-names>M</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Papazian</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Ashenberg</surname><given-names>O</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Vaishnav</surname><given-names>ED</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia</article-title><source>Cell</source><volume>177</volume><fpage>1915</fpage><lpage>1932</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.040</pub-id><pub-id pub-id-type="pmid">31130381</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>TC</given-names></name><name><surname>Gomes</surname><given-names>AC</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cxcr4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow</article-title><source>Journal of Experimental Medicine</source><volume>211</volume><fpage>2567</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1084/jem.20140457</pub-id><pub-id pub-id-type="pmid">25403444</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bednarski</surname><given-names>J.J</given-names></name><name><surname>Sleckman</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Lymphocyte development: integration of DNA damage response signaling</article-title><source>Advances in Immunology</source><volume>116</volume><fpage>175</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-394300-2.00006-5</pub-id><pub-id pub-id-type="pmid">23063077</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bednarski</surname><given-names>JJ</given-names></name><name><surname>Pandey</surname><given-names>R</given-names></name><name><surname>Schulte</surname><given-names>E</given-names></name><name><surname>White</surname><given-names>LS</given-names></name><name><surname>Chen</surname><given-names>BR</given-names></name><name><surname>Sandoval</surname><given-names>GJ</given-names></name><name><surname>Kohyama</surname><given-names>M</given-names></name><name><surname>Haldar</surname><given-names>M</given-names></name><name><surname>Nickless</surname><given-names>A</given-names></name><name><surname>Trott</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Bassing</surname><given-names>CH</given-names></name><name><surname>Payton</surname><given-names>JE</given-names></name><name><surname>Sleckman</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>209</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1084/jem.20151048</pub-id><pub-id pub-id-type="pmid">26834154</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyman</surname><given-names>O</given-names></name><name><surname>Ramsey</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>DM</given-names></name><name><surname>Sprent</surname><given-names>J</given-names></name><name><surname>Surh</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IL-7/anti-IL-7 mab complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia</article-title><source>Journal of Immunology</source><volume>180</volume><fpage>7265</fpage><lpage>7275</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.11.7265</pub-id><pub-id pub-id-type="pmid">18490726</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bredemeyer</surname><given-names>AL</given-names></name><name><surname>Helmink</surname><given-names>BA</given-names></name><name><surname>Innes</surname><given-names>CL</given-names></name><name><surname>Calderon</surname><given-names>B</given-names></name><name><surname>McGinnis</surname><given-names>LM</given-names></name><name><surname>Mahowald</surname><given-names>GK</given-names></name><name><surname>Gapud</surname><given-names>EJ</given-names></name><name><surname>Walker</surname><given-names>LM</given-names></name><name><surname>Collins</surname><given-names>JB</given-names></name><name><surname>Weaver</surname><given-names>BK</given-names></name><name><surname>Mandik-Nayak</surname><given-names>L</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Allen</surname><given-names>PM</given-names></name><name><surname>May</surname><given-names>MJ</given-names></name><name><surname>Paules</surname><given-names>RS</given-names></name><name><surname>Bassing</surname><given-names>CH</given-names></name><name><surname>Sleckman</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dna double-strand breaks activate a multi-functional genetic program in developing lymphocytes</article-title><source>Nature</source><volume>456</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/nature07392</pub-id><pub-id pub-id-type="pmid">18849970</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broudy</surname><given-names>VC</given-names></name><name><surname>Lin</surname><given-names>NL</given-names></name><name><surname>Kaushansky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro</article-title><source>Blood</source><volume>85</volume><fpage>1719</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">7535585</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broudy</surname><given-names>VC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Stem cell factor and hematopoiesis</article-title><source>Blood</source><volume>90</volume><fpage>1345</fpage><lpage>1364</lpage><pub-id pub-id-type="pmid">9269751</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broxmeyer</surname><given-names>HE</given-names></name><name><surname>Orschell</surname><given-names>CM</given-names></name><name><surname>Clapp</surname><given-names>DW</given-names></name><name><surname>Hangoc</surname><given-names>G</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Plett</surname><given-names>PA</given-names></name><name><surname>Liles</surname><given-names>WC</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Graham-Evans</surname><given-names>B</given-names></name><name><surname>Campbell</surname><given-names>TB</given-names></name><name><surname>Calandra</surname><given-names>G</given-names></name><name><surname>Bridger</surname><given-names>G</given-names></name><name><surname>Dale</surname><given-names>DC</given-names></name><name><surname>Srour</surname><given-names>EF</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>1307</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1084/jem.20041385</pub-id><pub-id pub-id-type="pmid">15837815</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancilla</surname><given-names>D</given-names></name><name><surname>Rettig</surname><given-names>MP</given-names></name><name><surname>DiPersio</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting CXCR4 in AML and all</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>1672</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.01672</pub-id><pub-id pub-id-type="pmid">33014834</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>P</given-names></name><name><surname>Le</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sabloff</surname><given-names>M</given-names></name><name><surname>Mehic</surname><given-names>J</given-names></name><name><surname>Rosu-Myles</surname><given-names>M</given-names></name><name><surname>Allan</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors</article-title><source>Leukemia Research</source><volume>39</volume><fpage>486</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2015.01.013</pub-id><pub-id pub-id-type="pmid">25703353</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Burkhardt</surname><given-names>DB</given-names></name><name><surname>Hartman</surname><given-names>AA</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Eastman</surname><given-names>AE</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>M</given-names></name><name><surname>Krishnaswamy</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mll-Af9 initiates transformation from fast-proliferating myeloid progenitors</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5767</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13666-5</pub-id><pub-id pub-id-type="pmid">31852898</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colmone</surname><given-names>A</given-names></name><name><surname>Amorim</surname><given-names>M</given-names></name><name><surname>Pontier</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Jablonski</surname><given-names>E</given-names></name><name><surname>Sipkins</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells</article-title><source>Science</source><volume>322</volume><fpage>1861</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1126/science.1164390</pub-id><pub-id pub-id-type="pmid">19095944</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comazzetto</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>MM</given-names></name><name><surname>Berto</surname><given-names>S</given-names></name><name><surname>Jeffery</surname><given-names>E</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Restricted hematopoietic progenitors and erythropoiesis require SCF from leptin receptor+ niche cells in the bone marrow</article-title><source>Stem Cell</source><volume>24</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.11.022</pub-id><pub-id pub-id-type="pmid">30661958</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordeiro Gomes</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Lim</surname><given-names>VY</given-names></name><name><surname>Herndler-Brandstetter</surname><given-names>D</given-names></name><name><surname>Nevius</surname><given-names>E</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Tani-Ichi</surname><given-names>S</given-names></name><name><surname>Schlenner</surname><given-names>S</given-names></name><name><surname>Richie</surname><given-names>E</given-names></name><name><surname>Rodewald</surname><given-names>H-R</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Ikuta</surname><given-names>K</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hematopoietic stem cell niches produce lineage-instructive signals to control multipotent progenitor differentiation</article-title><source>Immunity</source><volume>45</volume><fpage>1219</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.11.004</pub-id><pub-id pub-id-type="pmid">27913094</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Ansel</surname><given-names>KM</given-names></name><name><surname>Reif</surname><given-names>K</given-names></name><name><surname>Ekland</surname><given-names>EH</given-names></name><name><surname>Hyman</surname><given-names>PL</given-names></name><name><surname>Tang</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Follicular stromal cells and lymphocyte homing to follicles</article-title><source>Immunological Reviews</source><volume>176</volume><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1034/j.1600-065X.2000.00618.x</pub-id><pub-id pub-id-type="pmid">11043777</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>DC</given-names></name><name><surname>Firkin</surname><given-names>F</given-names></name><name><surname>Bolyard</surname><given-names>AA</given-names></name><name><surname>Kelley</surname><given-names>M</given-names></name><name><surname>Makaryan</surname><given-names>V</given-names></name><name><surname>Gorelick</surname><given-names>KJ</given-names></name><name><surname>Ebrahim</surname><given-names>T</given-names></name><name><surname>Garg</surname><given-names>V</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Skerlj</surname><given-names>R</given-names></name><name><surname>Beaussant Cohen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome</article-title><source>Blood</source><volume>136</volume><fpage>2994</fpage><lpage>3003</lpage><pub-id pub-id-type="doi">10.1182/blood.2020007197</pub-id><pub-id pub-id-type="pmid">32870250</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Saunders</surname><given-names>TL</given-names></name><name><surname>Enikolopov</surname><given-names>G</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endothelial and perivascular cells maintain haematopoietic stem cells</article-title><source>Nature</source><volume>481</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/nature10783</pub-id><pub-id pub-id-type="pmid">22281595</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches</article-title><source>Nature</source><volume>495</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/nature11885</pub-id><pub-id pub-id-type="pmid">23434755</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fistonich</surname><given-names>C</given-names></name><name><surname>Zehentmeier</surname><given-names>S</given-names></name><name><surname>Bednarski</surname><given-names>JJ</given-names></name><name><surname>Miao</surname><given-names>R</given-names></name><name><surname>Schjerven</surname><given-names>H</given-names></name><name><surname>Sleckman</surname><given-names>BP</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell circuits between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell development</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>2586</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.1084/jem.20180778</pub-id><pub-id pub-id-type="pmid">30158115</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geyh</surname><given-names>S</given-names></name><name><surname>Rodríguez-Paredes</surname><given-names>M</given-names></name><name><surname>Jäger</surname><given-names>P</given-names></name><name><surname>Khandanpour</surname><given-names>C</given-names></name><name><surname>Cadeddu</surname><given-names>R-P</given-names></name><name><surname>Gutekunst</surname><given-names>J</given-names></name><name><surname>Wilk</surname><given-names>CM</given-names></name><name><surname>Fenk</surname><given-names>R</given-names></name><name><surname>Zilkens</surname><given-names>C</given-names></name><name><surname>Hermsen</surname><given-names>D</given-names></name><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Kobbe</surname><given-names>G</given-names></name><name><surname>Lyko</surname><given-names>F</given-names></name><name><surname>Haas</surname><given-names>R</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia</article-title><source>Leukemia</source><volume>30</volume><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/leu.2015.325</pub-id><pub-id pub-id-type="pmid">26601782</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenbaum</surname><given-names>A</given-names></name><name><surname>Hsu</surname><given-names>Y-MS</given-names></name><name><surname>Day</surname><given-names>RB</given-names></name><name><surname>Schuettpelz</surname><given-names>LG</given-names></name><name><surname>Christopher</surname><given-names>MJ</given-names></name><name><surname>Borgerding</surname><given-names>JN</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Link</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cxcl12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance</article-title><source>Nature</source><volume>495</volume><fpage>227</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/nature11926</pub-id><pub-id pub-id-type="pmid">23434756</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>D</given-names></name><name><surname>Aplenc</surname><given-names>R</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Rheingold</surname><given-names>SR</given-names></name><name><surname>Teachey</surname><given-names>DT</given-names></name><name><surname>Chew</surname><given-names>A</given-names></name><name><surname>Hauck</surname><given-names>B</given-names></name><name><surname>Wright</surname><given-names>JF</given-names></name><name><surname>Milone</surname><given-names>MC</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Chimeric antigen receptor-modified T cells for acute lymphoid leukemia</article-title><source>The New England Journal of Medicine</source><volume>368</volume><fpage>1509</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1215134</pub-id><pub-id pub-id-type="pmid">23527958</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanoun</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Pierce</surname><given-names>H</given-names></name><name><surname>Kunisaki</surname><given-names>Y</given-names></name><name><surname>Lacombe</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Dührsen</surname><given-names>U</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche</article-title><source>Stem Cell</source><volume>15</volume><fpage>365</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.06.020</pub-id><pub-id pub-id-type="pmid">25017722</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrix</surname><given-names>CW</given-names></name><name><surname>Flexner</surname><given-names>C</given-names></name><name><surname>MacFarland</surname><given-names>RT</given-names></name><name><surname>Giandomenico</surname><given-names>C</given-names></name><name><surname>Fuchs</surname><given-names>EJ</given-names></name><name><surname>Redpath</surname><given-names>E</given-names></name><name><surname>Bridger</surname><given-names>G</given-names></name><name><surname>Henson</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>44</volume><fpage>1667</fpage><lpage>1673</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.6.1667-1673.2000</pub-id><pub-id pub-id-type="pmid">10817726</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hérault</surname><given-names>A</given-names></name><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Leong</surname><given-names>S</given-names></name><name><surname>Calero-Nieto</surname><given-names>FJ</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Kang</surname><given-names>Y-A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Chu</surname><given-names>SH</given-names></name><name><surname>Barry-Holson</surname><given-names>K</given-names></name><name><surname>Armstrong</surname><given-names>S</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis</article-title><source>Nature</source><volume>544</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature21693</pub-id><pub-id pub-id-type="pmid">28355185</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juarez</surname><given-names>J</given-names></name><name><surname>Dela Pena</surname><given-names>A</given-names></name><name><surname>Baraz</surname><given-names>R</given-names></name><name><surname>Hewson</surname><given-names>J</given-names></name><name><surname>Khoo</surname><given-names>M</given-names></name><name><surname>Cisterne</surname><given-names>A</given-names></name><name><surname>Fricker</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Bradstock</surname><given-names>KF</given-names></name><name><surname>Bendall</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cxcr4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment</article-title><source>Leukemia</source><volume>21</volume><fpage>1249</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404684</pub-id><pub-id pub-id-type="pmid">17410186</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</article-title><source>Science Translational Medicine</source><volume>3</volume><elocation-id>95ra73</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3002842</pub-id><pub-id pub-id-type="pmid">21832238</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>I-M</given-names></name><name><surname>Wilson</surname><given-names>CS</given-names></name><name><surname>Bedrick</surname><given-names>EJ</given-names></name><name><surname>Harvey</surname><given-names>RC</given-names></name><name><surname>Atlas</surname><given-names>SR</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Ar</surname><given-names>K</given-names></name><name><surname>Wharton</surname><given-names>W</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Bowman</surname><given-names>WP</given-names></name><name><surname>Bhojwani</surname><given-names>D</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Camitta</surname><given-names>BM</given-names></name><name><surname>Reaman</surname><given-names>GH</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Willman</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia</article-title><source>Blood</source><volume>115</volume><fpage>1394</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-05-218560</pub-id><pub-id pub-id-type="pmid">19880498</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TJ</given-names></name><name><surname>Upadhyay</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Innate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironment</article-title><source>The Journal of Experimental Medicine</source><volume>211</volume><fpage>1421</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1084/jem.20131501</pub-id><pub-id pub-id-type="pmid">24913234</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Janik</surname><given-names>JE</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Maric</surname><given-names>I</given-names></name><name><surname>Raffeld</surname><given-names>M</given-names></name><name><surname>Nathan</surname><given-names>D-AN</given-names></name><name><surname>Lanier</surname><given-names>BJ</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19</article-title><source>Blood</source><volume>116</volume><fpage>4099</fpage><lpage>4102</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-281931</pub-id><pub-id pub-id-type="pmid">20668228</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>VY</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>R</given-names></name><name><surname>Zehentmeier</surname><given-names>S</given-names></name><name><surname>Ewing-Crystal</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Tumanov</surname><given-names>AV</given-names></name><name><surname>Oh</surname><given-names>JE</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mature B cells and mesenchymal stem cells control emergency myelopoiesis</article-title><source>Life Science Alliance</source><volume>6</volume><elocation-id>e202301924</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202301924</pub-id><pub-id pub-id-type="pmid">36717247</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Boettcher</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Emergency granulopoiesis</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>302</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/nri3660</pub-id><pub-id pub-id-type="pmid">24751955</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maude</surname><given-names>SL</given-names></name><name><surname>Frey</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>PA</given-names></name><name><surname>Aplenc</surname><given-names>R</given-names></name><name><surname>Barrett</surname><given-names>DM</given-names></name><name><surname>Bunin</surname><given-names>NJ</given-names></name><name><surname>Chew</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>VE</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Lacey</surname><given-names>SF</given-names></name><name><surname>Mahnke</surname><given-names>YD</given-names></name><name><surname>Melenhorst</surname><given-names>JJ</given-names></name><name><surname>Rheingold</surname><given-names>SR</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Teachey</surname><given-names>DT</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chimeric antigen receptor T cells for sustained remissions in leukemia</article-title><source>The New England Journal of Medicine</source><volume>371</volume><fpage>1507</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1407222</pub-id><pub-id pub-id-type="pmid">25317870</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Méndez-Ferrer</surname><given-names>S</given-names></name><name><surname>Bonnet</surname><given-names>D</given-names></name><name><surname>Steensma</surname><given-names>DP</given-names></name><name><surname>Hasserjian</surname><given-names>RP</given-names></name><name><surname>Ghobrial</surname><given-names>IM</given-names></name><name><surname>Gribben</surname><given-names>JG</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name><name><surname>Krause</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bone marrow niches in haematological malignancies</article-title><source>Nature Reviews. Cancer</source><volume>20</volume><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0245-2</pub-id><pub-id pub-id-type="pmid">32112045</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>VY</given-names></name><name><surname>Kothapalli</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Fossati</surname><given-names>J</given-names></name><name><surname>Zehentmeier</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hematopoietic stem cell niches and signals controlling immune cell development and maintenance of immunological memory</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>600127</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.600127</pub-id><pub-id pub-id-type="pmid">33324418</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>R</given-names></name><name><surname>Chun</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Gomes</surname><given-names>AC</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Competition between hematopoietic stem and progenitor cells controls hematopoietic stem cell compartment size</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>4611</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-32228-w</pub-id><pub-id pub-id-type="pmid">35941168</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The bone marrow niche for haematopoietic stem cells</article-title><source>Nature</source><volume>505</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1038/nature12984</pub-id><pub-id pub-id-type="pmid">24429631</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munugalavadla</surname><given-names>V</given-names></name><name><surname>Kapur</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role of c-Kit and erythropoietin receptor in erythropoiesis</article-title><source>Critical Reviews in Oncology/Hematology</source><volume>54</volume><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2004.11.005</pub-id><pub-id pub-id-type="pmid">15780908</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Omatsu</surname><given-names>Y</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Oishi</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice</article-title><source>Blood</source><volume>117</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-277897</pub-id><pub-id pub-id-type="pmid">20944068</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>PS</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The LT beta R signaling pathway</article-title><source>Advances in Experimental Medicine and Biology</source><volume>597</volume><fpage>160</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1007/978-0-387-70630-6_13</pub-id><pub-id pub-id-type="pmid">17633025</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Haematopoietic stem cell activity and interactions with the niche</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>303</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0103-9</pub-id><pub-id pub-id-type="pmid">30745579</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>D.L</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia</article-title><source>The New England Journal of Medicine</source><volume>365</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103849</pub-id><pub-id pub-id-type="pmid">21830940</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Hwang</surname><given-names>WT</given-names></name><name><surname>Frey</surname><given-names>NV</given-names></name><name><surname>Lacey</surname><given-names>SF</given-names></name><name><surname>Shaw</surname><given-names>PA</given-names></name><name><surname>Loren</surname><given-names>AW</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>Marcucci</surname><given-names>KT</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>V</given-names></name><name><surname>Ambrose</surname><given-names>D</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Chew</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Milone</surname><given-names>MC</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Melenhorst</surname><given-names>JJ</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>303ra139</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aac5415</pub-id><pub-id pub-id-type="pmid">26333935</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>NN</given-names></name><name><surname>Fry</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanisms of resistance to CAR T cell therapy</article-title><source>Nature Reviews. Clinical Oncology</source><volume>16</volume><fpage>372</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/s41571-019-0184-6</pub-id><pub-id pub-id-type="pmid">30837712</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sipkins</surname><given-names>DA</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>JW</given-names></name><name><surname>Runnels</surname><given-names>JM</given-names></name><name><surname>Côté</surname><given-names>D</given-names></name><name><surname>Means</surname><given-names>TK</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>Lin</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment</article-title><source>Nature</source><volume>435</volume><fpage>969</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1038/nature03703</pub-id><pub-id pub-id-type="pmid">15959517</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Omatsu</surname><given-names>Y</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Niches for hematopoietic stem cells and immune cell progenitors</article-title><source>International Immunology</source><volume>31</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxy058</pub-id><pub-id pub-id-type="pmid">30169696</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikhonova</surname><given-names>AN</given-names></name><name><surname>Dolgalev</surname><given-names>I</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Sivaraj</surname><given-names>KK</given-names></name><name><surname>Hoxha</surname><given-names>E</given-names></name><name><surname>Cuesta-Domínguez</surname><given-names>Á</given-names></name><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Akhmetzyanova</surname><given-names>I</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Witkowski</surname><given-names>M</given-names></name><name><surname>Guillamot</surname><given-names>M</given-names></name><name><surname>Gutkin</surname><given-names>MC</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Marier</surname><given-names>C</given-names></name><name><surname>Diefenbach</surname><given-names>C</given-names></name><name><surname>Kousteni</surname><given-names>S</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Fooksman</surname><given-names>DR</given-names></name><name><surname>Butler</surname><given-names>JM</given-names></name><name><surname>Economides</surname><given-names>A</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Tsirigos</surname><given-names>A</given-names></name><name><surname>Aifantis</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The bone marrow microenvironment at single-cell resolution</article-title><source>Nature</source><volume>569</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1104-8</pub-id><pub-id pub-id-type="pmid">30971824</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumanov</surname><given-names>A</given-names></name><name><surname>Kuprash</surname><given-names>D</given-names></name><name><surname>Lagarkova</surname><given-names>M</given-names></name><name><surname>Grivennikov</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Shakhov</surname><given-names>A</given-names></name><name><surname>Drutskaya</surname><given-names>L</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Chervonsky</surname><given-names>A</given-names></name><name><surname>Nedospasov</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues</article-title><source>Immunity</source><volume>17</volume><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(02)00397-7</pub-id><pub-id pub-id-type="pmid">12354378</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzeng</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Cheng</surname><given-names>WC</given-names></name><name><surname>Lai</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Loss of CXCL12/SDF-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression</article-title><source>Blood</source><volume>117</volume><fpage>429</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-01-266833</pub-id><pub-id pub-id-type="pmid">20833981</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Foster</surname><given-names>SJ</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression</article-title><source>The Journal of Experimental Medicine</source><volume>199</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1084/jem.20031104</pub-id><pub-id pub-id-type="pmid">14707114</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>1771</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1084/jem.20041419</pub-id><pub-id pub-id-type="pmid">15939792</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berk</surname><given-names>LCJ</given-names></name><name><surname>van der Veer</surname><given-names>A</given-names></name><name><surname>Willemse</surname><given-names>ME</given-names></name><name><surname>Theeuwes</surname><given-names>MJGA</given-names></name><name><surname>Luijendijk</surname><given-names>MW</given-names></name><name><surname>Tong</surname><given-names>WH</given-names></name><name><surname>van der Sluis</surname><given-names>IM</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name><name><surname>den Boer</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia</article-title><source>British Journal of Haematology</source><volume>166</volume><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1111/bjh.12883</pub-id><pub-id pub-id-type="pmid">24697337</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Koroleva</surname><given-names>EP</given-names></name><name><surname>Kruglov</surname><given-names>AA</given-names></name><name><surname>Kuprash</surname><given-names>DV</given-names></name><name><surname>Nedospasov</surname><given-names>SA</given-names></name><name><surname>Fu</surname><given-names>Y-X</given-names></name><name><surname>Tumanov</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection</article-title><source>Immunity</source><volume>32</volume><fpage>403</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.02.011</pub-id><pub-id pub-id-type="pmid">20226692</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pegg</surname><given-names>LE</given-names></name><name><surname>Fütterer</surname><given-names>A</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Signal via lymphotoxin-beta R on bone marrow stromal cells is required for an early checkpoint of NK cell development</article-title><source>Journal of Immunology</source><volume>166</volume><fpage>1684</fpage><lpage>1689</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.3.1684</pub-id><pub-id pub-id-type="pmid">11160211</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Naito</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>J-I</given-names></name><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Santee-Cooper</surname><given-names>SM</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name><name><surname>Togawa</surname><given-names>A</given-names></name><name><surname>Nishikawa</surname><given-names>S</given-names></name><name><surname>Nishikawa</surname><given-names>S-I</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Different cytokines induce surface lymphotoxin-αβ on IL-7 receptor-α cells that differentially engender lymph nodes and Peyer’s patches</article-title><source>Immunity</source><volume>17</volume><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(02)00479-X</pub-id><pub-id pub-id-type="pmid">12479827</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehentmeier</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell circuits and niches controlling B cell development</article-title><source>Immunological Reviews</source><volume>289</volume><fpage>142</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1111/imr.12749</pub-id><pub-id pub-id-type="pmid">30977190</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehentmeier</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>VY</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Fossati</surname><given-names>J</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Tumanov</surname><given-names>AV</given-names></name><name><surname>Lee</surname><given-names>H-J</given-names></name><name><surname>Dillinger</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Csomos</surname><given-names>K</given-names></name><name><surname>Walter</surname><given-names>JE</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dysregulated stem cell niches and altered lymphocyte recirculation cause B and T cell lymphopenia in WHIM syndrome</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>eabo3170</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abo3170</pub-id><pub-id pub-id-type="pmid">36149943</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83533.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Méndez-Ferrer</surname><given-names>Simón</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.23.509256" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.23.509256"/></front-stub><body><p>This study investigates a novel pathway by which leukemic cells remodel the bone marrow niche to promote their expansion at the expense of normal hematopoiesis. Feng X, Pereira JP et al. convincingly demonstrate a positive feedback loop between leukemic cells and stromal cells mediated by lymphotoxin produced by cancer cells and its receptor expressed by bone marrow stromal cells. The authors provide compelling evidence suggesting that this pathway disrupts normal blood production and provides a competitive advantage to leukemic cells.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83533.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Méndez-Ferrer</surname><given-names>Simón</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.23.509256">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.09.23.509256v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin-β receptor signaling&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Tony Ng as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The consensus is that this is a very interesting potential novel axis by which leukemic cells impede normal hematopoiesis. Yet, additional important controls seem to be required to substantiate the pathway at play and exclude other effects (such as homing of leukemic cells, or leukemic cell burden possibly impacting IL7 expression), particularly for those experiments with partial effects, as explained in the recommendations by the reviewers. The unexpected effect of lymphotoxin reducing (instead of inducing) CXCL12, discrepancies among the effects on WT, preleukemic and leukemic cells and different results across figures should be clarified as well, following the reviewers' recommendations. Mislabelled axis with the 10-x format should be corrected as well.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>One weakness of this study is that some of the differences are very small or can vary, warranting cautious interpretation of the results. The effect of LTbR block in Figure 2I appears very small (no statistical test is shown). In Figure 6F and G, the effects were also very small. These results leave it unclear whether the positive feedback loop is pathologically important or not. In Figure 4, the effect of ALL cells on hematopoiesis is very weak in 4C but prominent in 4N. It was not clear from the figure legends whether these experiments carried out in different ways.</p><p>Regarding the contribution of CXCR4, it appears to be difficult to conclude that its effect is via an induction of lymphotoxin expression in leukemic cells. Rather it may simply affect stroma interaction.</p><p>To further support their conclusions, authors need to examine how DNA damage response induces the expression of lymphotoxin and/or how lymphotoxin receptor signaling suppresses the expression of IL7.</p><p>Others</p><p>In Supp Figure 5, red and blue bars to show time points are confusing (these are with no manipulations).</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1) Concerning statistics. Student's parametric t-test can only be used if the samples have a normal distribution (tested with a D'Agostino-Pearson or Shapiro-Wilk normality test). When normality is not reach (p&lt;0.05), the authors must perform a non-parametric Mann Whitney test. Of note, normality will never be reached with n&lt;4 samples. Furthermore, for two-tailed non parametric test and an α of 0.05, and according to the Mann-Whitney table, statistical significance cannot be reached for 3 vs. 3 or 4 vs. 3 samples per group. Please follow these rules.</p><p>2) p3, in the first paragraph of the second sub-section, the reference Zehentmeier et al., 2022 is not formatted</p><p>3) In the last sentence p3, the authors claim that there is a significant extension of mouse survival with the LTbR-Ig treatment. Statistics must be shown in the related Figure 2I.</p><p>4) p5, last sentence. I guess the authors meant that ALL numbers were significantly decreased and not increased?</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin-β receptor signaling&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Simón Méndez-Ferrer (Reviewing Editor) and Tony Ng (Senior Editor).</p><p>The manuscript has been greatly improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>– Additional discussion needs to be provided on the interplay between LTab, CXCL12, and IL7 for a more balanced interpretation and consideration of possible alternative explanations for the effects observed.</p><p>– The labelling of Figure 2D (LTbR-Ig and HEL-Ig) is inverted compared with the previous version.</p><p>– Normality and homoscedasticity tests are missing to support the Gaussian distribution and the use of t-tests.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The authors clarified why some of the differences were small in their experimental settings. These explanations are reasonable and difficult to address experimentally. However, other results from experiments using sophisticated genetic models, are mostly compelling. In addition, the authors made clear how DNA damage increased the expression of lymphotoxin (revised experiments in Figure 5). Overall, this manuscript is ready for publication. Congratulations on your meticulous and beautiful work.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Feedback on the manuscript for the authors</p><p>It would have been appreciated to have a revised version with track changes to better evaluate the revisions of the manuscript.</p><p>Concerning statistics:</p><p>The authors cannot take for granted the fact that previous studies mishandled statistics to justify their own mishandling. By doing so, the authors ask the reviewers and the audience of <italic>eLife</italic> to accept the fact that their interpretation could be wrong. A Gaussian distribution is a prerequisite to a t-test and there should be no discussion about that.</p><p>The labelling of Figure 2D has been inverted (LTbR-Ig and HEL-Ig).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83533.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>One weakness of this study is that some of the differences are very small or can vary, warranting cautious interpretation of the results. The effect of LTbR block in Figure 2I appears very small (no statistical test is shown). In Figure 6F and G, the effects were also very small. These results leave it unclear whether the positive feedback loop is pathologically important or not. In Figure 4, the effect of ALL cells on hematopoiesis is very weak in 4C but prominent in 4N. It was not clear from the figure legends whether these experiments carried out in different ways.</p></disp-quote><p>We thank the reviewer for the valuable criticisms.</p><p>The statistical analysis has been included in Figure 2I. The variability in its magnitude is merely technical for the following reasons. in vivo treatment with LTbR-Ig had to be performed under sub-optimal conditions. Ideally we would have preferred to treat mice bi-weekly to ensure full saturation but this was impossible for lack of sufficient antagonist (a generous gift from Biogen). The effects described with LTbR conditional KO mice are also sub-optimal because Lepr-cre can only effectively delete LTbR protein in ~ 80% of MSCs, despite being the best genetic strategy currently available for genomic targeting of MSCs. The result we think reflects the true physiological impact of the LTbR pathway in BCR-ABL ALL is that depicted in Figure 4P with Ltb-deficient ALLs, which shows a significant and more promising impact in ALL growth in vivo. Having said this, we agree with the reviewer that the physiological impact of LTbR signaling in MSCs, even though significant, is still modest and possibly better explored in combination therapy. For example, studies by others have shown a positive effect of IL7 in CAR-T therapy (Adachi et al. Nat. Biotech 2018) against solid tumors and perhaps our study will be useful for future studies examining the therapeutic potential of CAR-T and LTbR targeted therapies against leukemia. We revised the manuscript to include this discussion point.</p><disp-quote content-type="editor-comment"><p>Regarding the contribution of CXCR4, it appears to be difficult to conclude that its effect is via an induction of lymphotoxin expression in leukemic cells. Rather it may simply affect stroma interaction.</p></disp-quote><p>We agree with the reviewer. In fact we apologize for not making it clear that the effect of CXCR4 signaling is: First, by mediating physical interactions between ALL (and non-leukemic leukocytes) and MSCs in the BM. Second, by further promoting Lta1b2 expression in ALLs (as it does on B-lymphocytes, Ansel et al. Nature 2000), it potentiates IL7 downregulation in MSCs. We revised the manuscript to make this point clearer.</p><disp-quote content-type="editor-comment"><p>To further support their conclusions, authors need to examine how DNA damage response induces the expression of lymphotoxin and/or how lymphotoxin receptor signaling suppresses the expression of IL7.</p></disp-quote><p>We thank the reviewer for the valuable suggestion. We’ve spent a considerable amount of time studying how Il7 production is transcriptionally regulated. Unfortunately, we are still a long way from understanding it completely. This question alone is a project in of itself and thus we think it falls outside of the scope of this manuscript. Regarding the mechanisms driving Lymphotoxin a1b2 upregulation in leukemia cells, we hypothesized that by being induced by the DSB pathway (as Sleckman and colleagues have shown) that NFkB might be involved. We tested this possibility using small molecule antagonist of IKKb-mediated IkBa phosphorylation (IMD-0354) and found that it reduces LTa1b2 expression in ALLs treated with the DNA-damaging agent Etoposide. These data have been included in Figure 5—figure supplement 4 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Others</p><p>In Supp Figure 5, red and blue bars to show time points are confusing (these are with no manipulations).</p></disp-quote><p>We’ve corrected this figure in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1) Concerning statistics. Student's parametric t-test can only be used if the samples have a normal distribution (tested with a D'Agostino-Pearson or Shapiro-Wilk normality test). When normality is not reach (p&lt;0.05), the authors must perform a non-parametric Mann Whitney test. Of note, normality will never be reached with n&lt;4 samples. Furthermore, for two-tailed non parametric test and an α of 0.05, and according to the Mann-Whitney table, statistical significance cannot be reached for 3 vs. 3 or 4 vs. 3 samples per group. Please follow these rules.</p></disp-quote><p>We performed new experiments and revised most figures to included more mice. However, in some cases, we did not change the original figures for ethical reasons. For example, in Figure 1 we show dramatic effects of ALL growth in hematopoietic lineages after 21 days by examining 3 mice. The impact is so large that we consider it unethical to perform additional experiments for a sole statistical purpose. Furthermore, numerous studies have included parametric student’s t test analyses for n&lt;4 samples (including many studies on bone marrow niches; for an example see Fujisaki et al. Nature 2011).</p><disp-quote content-type="editor-comment"><p>2) p3, in the first paragraph of the second sub-section, the reference Zehentmeier et al., 2022 is not formatted</p></disp-quote><p>This has been corrected.</p><disp-quote content-type="editor-comment"><p>3) In the last sentence p3, the authors claim that there is a significant extension of mouse survival with the LTbR-Ig treatment. Statistics must be shown in the related Figure 2I.</p></disp-quote><p>This has been included.</p><disp-quote content-type="editor-comment"><p>4) p5, last sentence. I guess the authors meant that ALL numbers were significantly decreased and not increased?</p></disp-quote><p>This has been corrected.</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been greatly improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>– Additional discussion needs to be provided on the interplay between LTab, CXCL12, and IL7 for a more balanced interpretation and consideration of possible alternative explanations for the effects observed.</p></disp-quote><p>In the revised manuscript we now include two new panels in Figure 5 (J and K) that show increased CXCR4 expression and CXCR4-mediated migration to CXCL12 in ALLs when compared to either small or large preB cells. We believe these data lend support to a model where ALLs are more competent than non-leukemic B cell progenitors in homing and retention in BM even when its ligand CXCL12 expression is slightly downregulated.</p><disp-quote content-type="editor-comment"><p>– The labelling of Figure 2D (LTbR-Ig and HEL-Ig) is inverted compared with the previous version.</p></disp-quote><p>We apologize for the oversight; this has been corrected.</p><disp-quote content-type="editor-comment"><p>– Normality and homoscedasticity tests are missing to support the Gaussian distribution and the use of t-tests.</p></disp-quote><p>A new table 4 has been included. This table contains Normality and homoscedasticity tests for all experimental groups.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):Feedback on the manuscript for the authors</p><p>It would have been appreciated to have a revised version with track changes to better evaluate the revisions of the manuscript.</p><p>Concerning statistics:</p><p>The authors cannot take for granted the fact that previous studies mishandled statistics to justify their own mishandling. By doing so, the authors ask the reviewers and the audience of eLife to accept the fact that their interpretation could be wrong. A Gaussian distribution is a prerequisite to a t-test and there should be no discussion about that.</p></disp-quote><p>A new table 4 includes normality tests for all experimental groups examined in this study.</p><disp-quote content-type="editor-comment"><p>The labelling of Figure 2D has been inverted (LTbR-Ig and HEL-Ig).</p></disp-quote><p>This has been corrected.</p></body></sub-article></article>